ニューモシスチス肺炎のすべて

出版社： 克誠堂出版
著者：
発行日： 2014-03-10
分野： 臨床医学：内科  >  呼吸器一般
ISBN： 9784771904200
電子書籍版： 2014-03-10 （第1版第2刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

6,380 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

6,380 円(税込)

購入する

商品紹介

本邦初、PCPのテキストBOOK！ HIVとnon-HIVにおけるPCPの違いは？ 診断、治療、予防から症例まで、PCPのすべてを網羅。呼吸器、感染症、膠原病、腎移植、血液悪性腫瘍、臨床検査、放射線の専門家が集結！

目次

  • ニューモシスチス肺炎のすべて

    ―目次―

    1．序論
    2．ヒトに感染・定着する微生物としてのPneumocystis
    3．PCP総論（HIVからnon-HIVまで）
    　 歴史・病態・病原体の疫学
    4．診断
    　 1）微生物学的診断
    　 2）血清学的診断
    　 3）画像診断
    　　 a. HIV
    　　 b. Non-HIV
    5．治療
    　 1）ST合剤
    　 2）その他
    　 3）副腎皮質ステロイド
    　 4）集中治療
    6．予防
    7．院内感染の制御

    II．各論
    1．HIV-PCP
    　 1）疫学（日本・世界）
    　 2）診断
    　 3）治療
    　 4）予後
    　 5）予防
    　 ＜CASE1＞
    　 ＜CASE2＞
    2．Non-HIV-PCP
    　 1）RAその他自己免疫疾患
    　　 a. RA以外の膠原病（SLE，GPAを中心に）
    　　 ＜CASE＞
    　　 b. RA薬物療法に伴うPCP
    　　 ＜CASE1＞
    　　 ＜CASE2＞
    　 2）血液・悪性腫瘍
    　 ＜CASE1＞
    　 ＜CASE2＞
    　 ＜CASE3＞
    　 3）移植
    　 ＜CASE＞

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

[I] 総論

P.11 掲載の参考文献
1. 吉田幸雄. ニューモシスチスカリニ肺炎. 東京 : 南山堂, 1981.
 
2. 山口英世. ニューモシスチスとはどんな微生物か? : その生物学と分類学を中心に. モダンメディア 2011 ; 57 : 125-45.
 
3. Morris A, Norris K. Colonization by Pneumocystis jirovecii and its role in disease. Clin Microbiol Rev 2013 ; 25 : 297-317.
 
4. De Stefano JA, Walzer PD. New biological insights. In : Sattler FR, Walzer PD, editors. Bailliele's clinical infectious diseases : International practice and research. vol 2 No 3. Pneumocystis carinii. London : Bailliele Tindall, 1995 : 415-30.
 
5. Frenkel JK. Pneumocystis pneumonia, an immunodeficiency-dependent disease (IDD) : a critical historical overview. J Eukaryot Microbiol 1999 ; 46 : 89S-92S.
 
6. 日本医真菌学会用語委員会. 医真菌関連起因菌の分類と学名に関する小委員会資料 (学名の日本語表示に関する見解ならびに日本語表記法に関する検討) 改訂6.1版 2007年11月7日. http://www.jsmm.org/Pneumocystis_jirovecii.pdf (2013年8月14日接続).
 
7. Cavalier-Smith T. What are fungi? In : McLaughlin DJ, McLaughlin EG, Lemke PA, editors. The mycota Vol. 7A. Berlin : Springer, 2001.
 
8. Edman JC, Kovacs JA, Masur H, et al. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 1988 ; 334 : 519-22.
PubMed
9. Liu Y, Rocourt M, Pan S, et al. Sequence and variability of the 5. 8S and 26S rRNA genes of Pneumocystis carinii. Nucleic Acids Res 1992 ; 20 : 3763-72.
PubMed
10. Ypma-Wong MF, Fonzi WA, Sypherd PS. Fungus-specific translation elongation factor 3 gene present in Pneumocystis carinii. Infect Immun 1992 ; 60 : 4140-45.
PubMed
11. Makimura K, Murayama SY, Yamaguchi H. Detection of a wide range of medically important fungi by the polymerase chain reaction. J Med Microbiol 1994 ; 40 : 358-64.
PubMed
12. Vavra J, Kucera K. Pneumocystis carinii Delanoe, its ultrastructure and ultrastructure affinities. J Protozool 1970 ; 17 : 463-83.
PubMed
13. Matsumoto Y, Yoshida M, Amagi T, et al. Yeast glucan of Pneumocystis carinii cyst wall : an excellent target for chemotherapy. J Protozool 1991 ; 38 : 6S-7S.
 
14. Schmatz D, Powles MA, McFadden D, et al. New semisynthetic pneumocandins with improved efficacies against Pneumocystis carinii in rat. Antimicrob Agents Chemoter 1995 ; 39 : 1320-3.
PubMed
15. Kurtzman CP, Fell JW, Boekhout T, editors. The Yeasts, a Taxonomic Study, 5th ed. Amsterdam : Elsevier, 2011.
 
16. Pappagianis D. Coccidioides immitis. In : Ajello L, Hay RJ, editors. Topley & Wilson's microbiology and microbial infections, vol 4. Medical mycology. London : Arnold, 1998 : 357-71.
 
17. Schuh JC, Harrington KA, Fanslow WC. Terminology changes needed for descriptions of Pneumocystis carinii infection. Infect Immun 1997 ; 65 : 1135-6.
PubMed
18. Cushion MT, Walzer PD, Smulian AG, et al. Terminology for the life cycle of Pneumocystis carinii. Infect Immun 1997 ; 65 : 4365 ; discussion 4366.
 
19. Aliouat-Denis CM, Martinez A, Aliouat el M, et al. The Pneumocystis life cycle. Mem Inst Oswaldo Cruz 2009 ; 104 : 419-26.
PubMed
20. Matsumoto Y, Yoshida Y. Sporogony in Pneumocystis carinii : synaptonemal complexes and meiotic nuclear divisions observed in precysts. J Protozool 1984 ; 31 : 420-8.
PubMed
21. Beck JM, Cushion MT. Pneumocystis workshop : 10th anniversary summary. Eukaryot Cell 2009 ; 8 : 446-60.
PubMed
22. Gigliotti F, Harmsen AG, Haidaris CG, et al. Pneumocystis carinii is not universally transmissible between mammalian species. Infect Immun 1993 ; 61 : 2886-90.
 
23. Cushion MT, Ebbets D. Growth and metabolism of Pneumocystis carinii in axenic culture. J Clin Microbiol 1990 ; 28 : 1385-94.
PubMed
24. Nolan A, Lamey PJ, MacFarlane TW, et al. The effect of nebulised pentamidine on the concentration of intra-oral Candida albicans in HIV-infected patients. J Med Microbiol 1994 ; 41 : 95-7.
PubMed
25. Joffrion TM, Cushion MT. Sterol biosynthesis and uptake in the fungal pathogen Pneumocystis carinii. FEMS Microbiol Lett 2010 ; 311 : 1-9.
PubMed
26. Peglow SL, Smulian AG, Linke MJ, et al. Serologic responses to Pneumocystis carinii antigens in health and disease. J Infect Dis 1990 ; 161 : 296-306.
 
27. Pifer LL, Hughes WT, Stagno S, et al. Pneumocystis carinii infection : evidence for high prevalence in normal and immunosuppressed children. Pediatrics 1978 ; 61 : 35-41.
PubMed
28. Navin TR, Rimland D, Lennox JL, et al. Risk factors for community-acquired pneumonia among persons infected with human immunodeficiency virus. J Infect Dis 2000 ; 181 : 158-64.
PubMed
29. Leigh TR, Kangro HO, Gazzard BG, et al. DNA amplification by the polymerase chain reaction to detect sub-clinical Pneumocystis carinii colonization in HIV-positive and HIV-negative male homosexuals with and without respiratory symptoms. Respir Med 1993 ; 87 : 525-9.
PubMed
30. Vargas SL, Pizarro P, Lopez-Vieyra M, et al. Pneumocystis colonization in older adults and diagnostic yield of single versus paired noninvasive respiratory sampling. Clin Infect Dis 2010 ; 50 : e19-e21.
PubMed
31. Ponce CA, Gallo M, Bustamante R, et al. Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population. Clin Infect Dis 2010 ; 50 : 347-53.
PubMed
32. de Boer MG, de Fijter JW, Kroon FP. Outbreaks and clustering of Pneumocystis pneumonia in kidney transplant recipients : a systematic review. Med Mycol 2011 ; 49 : 673-80.
PubMed
33. An CL, Gigliotti F, Harmsen AG. Exposure of immunocompetent adult mice to Pneumocystis carinii f. sp. muris by cohousing : growth of P. carinii f. sp. muris and host immune response. Infect Immun 2003 ; 71 : 2065-70.
PubMed
34. Gigliotti F, Harmsen AG, Wright TW. Characterization of transmission of Pneumocystis carinii f. sp. muris through immunocompetent BALB/c mice. Infect Immun 2003 ; 71 : 3852-6.
PubMed
35. 日本医真菌学会教育委員会. 我が国の医真菌教育の実態 : アンケート調査による. 真菌誌 2004 ; 45 : 121-2.
 
P.17 掲載の参考文献
1. Chagas C. Nova tripanosomiaze humana : estudo sobre a morfolojia e o evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem. Mem Inst Oswaldo Cruz 1909 ; 1 : 159-218.
 
2. Carinii A. Formas de eschizogonia do Trypanozoma lewisi. Commun Soc Med Sao Paolo 1910 ; 16 : 204.
 
3. van der Meer MG, Brug SL. Infection a Pneumocystis chez l'homme et chez les animaux. Ann Soc Belge Med Trop 1942 ; 22 : 301-9.
 
4. Jirovec O. Pneumocystis carinii puvodce t. zv intertitialnich plasmocelularnich pneumonii kojencw. Csl Hyg Epid Mikrob 1952 ; 1 : 141.
 
5. Thomas CF Jr, Limper, AH. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol 2007 ; 5 : 298-308.
PubMed
6. Beck JM, Cushion MT. Pneumocystis Workshop : 10th Anniversary Summary. Eukaryotic Cell 2009 ; 8 : 446-60.
PubMed
7. Walzer PD, Perl DP, Krogstad DJ, et al. Pneumocystis carinii pneumonia in the United States : epidemiologic, diagnostic, and clinical features. Ann Intern Med 1974 ; 80 : 83-93.
PubMed
8. Morris A, Lundgren JD, Masur H, et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 2004 ; 10 : 1713-20.
PubMed
9. Murray JF. Pulmonary complications of HIV-1 infection among adults living in Sub-Saharan Africa. Int J Tuberc Lung Dis 2005 ; 9 : 826-35.
PubMed
10. Stringer JR, Beard CB, Miller RF, et al. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis 2002 ; 8 : 891-6.
PubMed
11. Pifer LL, Hughes WT, Stagno S, et al. Pneumocystis carinii infection : evidence for high prevalence in normal and immunosuppressed children. Pediatrics 1978 ; 61 : 35-41.
PubMed
12. Morris A, Wei K, Afshar K, et al. Epidemiology and clinical significance of Pneumocystis colonization. J Infect Dis 2008 ; 197 : 10-7.
PubMed
13. Medrano FJ, Montes-Cano M, Conde M, et al. Pneumocystis jirovecii in general population. Emerg Infect Dis 2005 ; 11 : 245-50.
PubMed
14. Maskell NA, Waine DJ, Lindley A, et al. Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy : a prospective study. Thorax 2003 ; 58 : 594-7.
PubMed
15. Mekinian A, Durand-Joly I, Hatron PY, et al. Pneumocystis jirovecii colonization in patients with systemic autoimmune diseases : prevalence, risk factors of colonization and outcome. Rheumatology 2011 ; 50 : 569-77.
PubMed
16. Wissmann G, Morilla R, Martin-Garrido I, et al. Pneumocystis jirovecii colonization in patients treated with infliximab. Eur J Clin Invest 2011 ; 41 : 343-8.
PubMed
17. Miller RF, Ambrose HE, Wakefield AE. Pneumocystis carinii f. sp. hominis DNA in immunocompetent health care workers in contact with patients with P. carinii pneumonia. J Clin Microbiol 2001 ; 39 : 3877-82.
 
18. Durand-Joly I, Soula F, Chabe M, et al. Long-term colonization with Pneumocystis jirovecii in hospital staffs : a challenge to prevent nosocomial pneumocystosis. J Eukaryot Microbiol 2003 ; 50 Suppl : 614-5.
PubMed
19. Ponce CA, Gallo M, Bustamante R, et al. Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population. Clin Infect Dis 2010 ; 50 : 347-53.
PubMed
20. Huang L, Morris A, Limper AH, et al. An official ATS workshop summary : Recent advances and future directions in Pneumocystis pneumonia. Proc Am Thorac Soc 2006 ; 3 : 655-64.
PubMed
21. Keely SP, Stringer JR. Sequences of Pneumocystis carinii f. sp. hominis strains associated with recurrent pneumonia vary at multiple loci. J Clin Microbiol 1997 ; 35 : 2745-7.
PubMed
22. Yazaki H, Goto N, Uchida K, et al. Outbreak of Pneumocystis jiroveci pneumonia in renal transplant recipients : P. jiroveci is contagious to the susceptible host. Transplantation 2009 ; 88 : 380-5.
 
23. Schmoldt S, Schuhegger R, Wendler T, et al. Molecular evidence of nosocomial Pneumocystis jirovecii transmission among 16 patients after kidney transplantation. J Clin Microbiol 2008 ; 46 : 966-71.
PubMed
24. Mori S, Cho I, Sugimoto M. A followup study of asymptomatic carriers of Pneumocystis jiroveci during immunosuppressive therapy for rheumatoid arthritis. J Rheumatol 2009 ; 36 : 1600-5.
 
25. Thomas CF Jr, Limper AH. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol 2007 ; 5 : 298-308.
PubMed
26. Gigliotti F, Wright TW. Immunopathogenesis of Pneumosystis carinii pneumonia. Expert Rev Mol Med 2005 ; 7 : 1-16.
 
27. Vassallo R, Standing JE, Limper AH. Isolated Pneumocystis carinii cell wall glucan provokes lower respiratory tract inflammatory responses. J Immunol 2000 ; 164 : 3755-63.
PubMed
28. Saijo S, Fujikado N, Furuta T, et al. Dectin-1 is required for host defense against Pneumocystis carinii but not against Candida albicans. Nat Immunol 2007 ; 8 : 39-46.
 
29. Drummond RA, Brown GD. The role of Dectin-1 in the host defence against fungal infections. Curr Opin Microbiol 2011 ; 14 : 392-9.
PubMed
30. Limper AH, Hoyte JS, Standing JE. The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung. J Clin Invest 1997 ; 99 : 2110-7.
 
31. Benfield TL, Vestbo J, Junge J, et al. Prognostic value of interleukin-8 in AIDS-associated Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1995 ; 151 : 1058-62.
PubMed
32. Wright TW, Gigliotti F, Finkelstein JN, et al. Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia. J Clin Invest 1999 ; 104 : 1307-17.
 
33. Roths JB, Marshall JD, Allen RD, et al. Spontaneous Pneumocystis carinii pneumonia in immunodeficient mutant SCID mice. Natural history and pathobiology. Am J Pathol 1990 ; 136 : 1173-86.
PubMed
34. Tasaka S, Tokuda H. Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies. J Infect Chemother 2012 ; 18 : 793-806.
PubMed
35. Reid AB, Chen SC, Worth LJ. Pneumocystis jirovecii pneumonia in non-HIV-infected patients : new risks and diagnostic tools. Curr Opin Infect Dis 2011 ; 24 : 534-44.
PubMed
36. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome. Mayo Clin Proc 1996 ; 71 : 5-13.
PubMed
37. Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia : a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984 ; 100 : 663-71.
PubMed
38. Calderon EJ, Gutierrez-Rivero S, Durand-Joly I, et al. Pneumocystis infection in humans : diagnosis and treatment. Expert Rev Anti Infect Ther 2010 ; 8 : 683-701.
PubMed
39. Limper AH, Offord KP, Smith TF, et al. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989 ; 140 : 1204-9.
PubMed
40. Tasaka S, Kobayashi S, Kamata H, et al. Cytokine profiles of bronchoalveolar lavage fluid in patients with Pneumocystis pneumonia. Microbiol Immunol 2010 ; 54 : 425-33.
PubMed
P.27 掲載の参考文献
1. Chagas C. Nova tripanosomiaze humana. Memorias de Institute Oswaldo Cruz Rio J 1909 ; 1 : 159-218.
 
2. Kovacs JA, Masur H. Evolving health effects of Pneumocystis : one hundred years of progress in diagnosis and treatment. JAMA 2009 ; 301 : 2578-85.
PubMed
3. Elie A, Anne B, Sylvie C, et al. Polymerase chain reaction for diagnosing Pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates. Chest 2009 ; 135 : 655-61.
 
4. Uemura N, Makimura K, Otsuka Y, et al. Development of a loop-mediated isothermal amplification method for diagnosing Pneumocystis pneumonia. J Med Microbiol 2008 ; 57 : 50-7.
PubMed
5. 橋本幸平, 大塚喜人, 能登勝宏, ほか. PCP診断におけるLAMP法の臨床的有用性. 第61回日本医学検査学会抄録 (2012年5月, 三重).
 
6. Brancart F, Rodriguez-Villalobos H, Fonteyne PA, et al. Quantitative TaqMan PCR for detection of Pneumocystis jirovecii. J Microbiol Methods 2005 ; 61 : 381-7.
 
7. Atzori C, Agostoni F, Angeli E, et al. Combined use of blood and oropharyngeal samples for noninvasive diagnosis of Pneumocystis carinii pneumonia using the polymerase chain reaction. Eur J Clin Microbiol Infect Dis 1998 ; 17 : 241-6.
PubMed
8. 大楠清文, 江崎孝行. 遺伝子技術を用いた肺炎の起炎菌診断の実践. 医学のあゆみ. 2011 ; 237 : 193-9.
 
P.33 掲載の参考文献
1. Obayashi T, Yoshida M, Mori T, et al. Plasma (1 → 3) -beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995 ; 345 : 17-20.
 
2. Mori T, Ikemoto H, Matsumura M, et al. Evaluation of plasma (1 → 3) -beta-D-glucan measurement by the kinetic turbidimetric Limulus test, for the clinical diagnosis of mycotic infections. Eur J Clin Chem Clin Biochem 1997 ; 35 : 553-60.
 
3. 深在性真菌症のガイドライン作成委員会, 編. 血清診断. 深在性真菌症の診断・治療ガイドライン 2007. 東京 : 協和企画, 2008 : 45-8.
 
4. Matsumoto Y, Matsuda S, Tegoshi T. Yeast glucan in the cyst wall of Pneumocystis carinii. J Protozool 1989 ; 36 : 21S-2S.
PubMed
5. Yasuoka A, Tachikawa N, Shimada K, et al. (1-3) beta-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin Diagn Lab Immunol 1996 ; 3 : 197-9.
PubMed
6. Obayashi T, Negishi K, Suzuki T, et al. Reappraisal of the serum (1→3) -b-D-glucan assay for the diagnosis of invasive fungal infections : a study based on autopsy cases from 6 years. Clin Infect Dis 2008 ; 46 : 1864-70.
 
7. Onishi A, Sugiyama D, Kogata Y, et al. Diagnostic accuracy of serum 1, 3-b-D-glucan for Pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis : systematic review and meta-analysis. J Clin Microbiol 2012 ; 50 : 7-15.
 
8. Marty FM, Koo S, Bryar J, et al. (1 → 3) beta-D-glucan assay positivity in patients with Pneumocystis (carinii) jiroveci pneumonia. Ann Intern Med 2007 ; 147 : 70-2.
 
9. Tasaka S, Hasegawa N, Kobayashi S, et al. Serum indicators for the diagnosis of pneumocystis pneumonia. Chest 2007 ; 131 : 1173-80.
 
10. Tokuda H, Sakai F, Yamada H, et al. Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome : a multicenter study. Intern Med 2008 ; 47 : 915-23.
PubMed
11. Nakamura H, Tateyama M, Tasato D, et al. Clinical utility of serum b-D-glucan and KL-6 levels in Pneumocystis jirovecii pneumonia. Intern Med 2009 ; 48 : 195-202.
 
12. Koga M, Koibuchi T, Kikuchi T, et al. Kinetics of serum b-D-glucan after Pneumocystis pneumonia treatment in patients with AIDS. Intern Med 2011 ; 50 : 1397-401.
 
13. 藤井毅. ニューモシスチス肺炎. 日本臨床 2008 ; 66 : 2367-72.
Medical*Online
14. 茂呂寛, 塚田弘樹, 小原竜軌, ほか. 臨床検体を用いた血中 (1 → 3) -b-D-グルカン測定キット4種類の比較検討. 感染症誌 2003 ; 77 : 227-34.
 
15. Watanabe T, Yasuoka A, Tanuma J, et al. Serum (1→3) beta-D-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis 2009 ; 49 : 1128-31.
 
16. Hamada H, Kohno N, Yokoyama A, et al. KL-6 as a serologic indicator of Pneumocystis carinii pneumonia in immunocompromised hosts. Intern Med 1998 ; 37 : 307-10.
PubMed
17. Tanaka M, Tanaka K, Fukahori S, et al. Elevation of serum KL-6 levels in patients with hematological malignancies associated with cytomegalovirus or Pneumocystis carinii pneumonia. Hematology 2002 ; 7 : 105-8.
PubMed
18. Quist J, Hill AR. Serum lactate dehydrogenase (LDH) in Pneumocystis carinii pneumonia, tuberculosis, and bacterial pneumonia. Chest 1995 ; 108 : 415-8.
PubMed
19. de Boer MG, Gelinck LB, van Zelst BD, et al. b-D-glucan and S-adenosylmethionine serum levels for the diagnosis of Pneumocystis pneumonia in HIV-negative patients : a prospective study. J Infect 2011 ; 62 : 93-100.
 
20. Skelly M, Hoffman J, Fabbri M, et al. S-adenosylmethionine concentrations in diagnosis of Pneumocystis carinii pneumonia. Lancet 2003 ; 361 : 1267-8.
PubMed
21. Skelly MJ, Holzman RS, Merali S. S-adenosylmethionine levels in the diagnosis of Pneumocystis carinii pneumonia in patients with HIV infection. Clin Infect Dis 2008 ; 46 : 467-71.
 
22. Wang P, Huang L, Davis JL, et al. A hydrophilic-interaction chromatography tandem mass spectrometry method for quantitation of serum s-adenosylmethionine in patients infected with human immunodeficiency virus. Clin Chim Acta 2008 ; 396 : 86-8.
PubMed
P.42 掲載の参考文献
1. Phair J, Munoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med 1990 ; 322 : 161-5.
 
2. Conces DJ Jr, Kraft JL, Vix VA, et al. Apical Pneumocystis carinii pneumonia after inhaled pentamidine prophylaxis. AJR Am J Roentgenol 1989 ; 152 : 1193-4.
PubMed
3. Allen CM, Al-Jahdali HH, Irion KL, et al. Imaging lung manifestations of HIV/AIDS. Ann Thorac Med 2010 ; 5 : 201-16.
PubMed
4. DeLorenzo LJ, Huang CT, Maguire GP, et al. Roentgenographic patterns of Pneumocystis carinii pneumonia in 104 patients with AIDS. Chest 1987 ; 91 : 323-7.
PubMed
5. Boiselle PM, Tocino I, Hooley RJ, et al. Chest radiograph interpretation of Pneumocystis carinii pneumonia, bacterial pneumonia, and pulmonary tuberculosis in HIV-positive patients : accuracy, distinguishing features, and mimics. J Thorac Imaging 1997 ; 12 : 47-53.
PubMed
6. Amin Z, Miller RF, Shaw PJ. Lobar or segmental consolidation on chest radiographs of patients with HIV infection. Clin Radiol 1997 ; 52 : 541-5.
PubMed
7. Sandhu JS, Goodman PC. Pulmonary cysts associated with Pneumocystis carinii pneumonia in patients with AIDS. Radiology 1989 ; 173 : 33-5.
PubMed
8. Chow C, Templeton PA, White CS. Lung cysts associated with Pneumocystis carinii pneumonia : radiographic characteristics, natural history, and complications. AJR Am J Roentgenol 1993 ; 161 : 527-31.
PubMed
9. Pastores SM, Garay SM, Naidich DP, et al. Review : pneumothorax in patients with AIDS-related Pneumocystis carinii pneumonia. Am J Med Sci 1996 ; 312 : 229-34.
PubMed
10. Takahashi T, Hoshino Y, Nakamura T, et al. Mediastinal emphysema with Pneumocystis carinii pneumonia in AIDS. AJR Am J Roentgenol 1997 ; 169 : 1465-6.
PubMed
11. Boiselle PM, Crans CA Jr, Kaplan MA. The changing face of Pneumocystis carinii pneumonia in AIDS patients. AJR Am J Roentgenol 1999 ; 172 : 1301-9.
PubMed
12. Goodman PC. Pneumocystis carinii pneumonia. J Thorac Imaging 1991 ; 6 : 16-21.
PubMed
13. Kuhlman JE. Pneumocystic infections : the radiologist's perspective. Radiology 1996 ; 198 : 623-35.
 
14. Gruden JF, Huang L, Turner J, et al. High-resolution CT in the evaluation of clinically suspected Pneumocystis carinii pneumonia in AIDS patients with normal, equivocal, or nonspecific radiographic findings. AJR Am J Roentgenol 1997 ; 169 : 967-75.
PubMed
15. Kanne JP, Yandow DR, Meyer CA. Pneumocystis jiroveci pneumonia : high-resolution CT findings in patients with and without HIV infection. AJR Am J Roentgenol 2012 ; 198 : W555-61.
PubMed
16. Vogel MN, Brodoefel H, Hierl T, et al. Differences and similarities of cytomegalovirus and pneumocystis pneumonia in HIV-negative immunocompromised patients thin section CT morphology in the early phase of the disease. Br J Radiol 2007 ; 80 : 516-23.
PubMed
17. Kuhlman JE, Kavuru M, Fishman EK, et al. Pneumocystis carinii pneumonia : spectrum of parenchymal CT findings. Radiology 1990 ; 175 : 711-4.
PubMed
18. Tasaka S, Tokuda H, Sakai F, et al. Comparison of clinical and radiological features of pneumocystis pneumonia between malignancy cases and acquired immunodeficiency syndrome cases : a multicenter study. Intern Med 2010 ; 49 : 273-81.
 
19. Hartman TE, Primack SL, Muller NL, et al. Diagnosis of thoracic complications in AIDS : accuracy of CT. AJR Am J Roentgenol 1994 ; 162 : 547-53.
PubMed
20. Fujii T, Nakamura T, Iwamoto A. Pneumocystis pneumonia in patients with HIV infection : clinical manifestations, laboratory findings, and radiological features. J Infect Chemother 2007 ; 13 : 1-7.
PubMed
21. Travis WD, Pittaluga S, Lipschik GY, et al. Atypical pathologic manifestations of Pneumocystis carinii pneumonia in the acquired immune deficiency syndrome. Review of 123 lung biopsies from 76 patients with emphasis on cysts, vascular invasion, vasculitis, and granulomas. Am J Surg Pathol 1990 ; 14 : 615-25.
PubMed
22. Webb WR, Muller NL, Naidich DP. Standardized terms for high-resolution computed tomography of the lung : a proposed glossary. J Thorac Imaging 1993 ; 8 : 167-75.
 
23. Padley SP, King LJ. Computed tomography of the thorax in HIV disease. Eur Radiol 1999 ; 9 : 1556-69.
PubMed
24. Leal FE, Cavazzana CL, de Andrade HF Jr, et al. Toxoplasma gondii pneumonia in immunocompetent subjects : case report and review. Clin Infect Dis 2007 ; 44 : e62-6.
PubMed
P.49 掲載の参考文献
1. Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia : a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984 ; 100 : 663-71.
PubMed
2. Limper AH, Offord KP, Smith TF, et al. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989 ; 140 : 1204-9.
PubMed
3. Sepkowitz KA. Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clin Infect Dis 2002 ; 34 : 1098-107.
PubMed
4. Thomas CF, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004 ; 350 : 2487-98.
PubMed
5. Kuhlman JE, Kavuru M, Fishman EK, et al. Pneumocystis carinii pneumonia : spectrum of parenchymal CT findings. Radiology 1990 ; 175 : 711-4.
PubMed
6. Kuhlman JE. Pneumocystic infections : the radiologist's perspective. Radiology 1996 ; 198 : 623-35.
 
7. Bergin CJ, Wirth RL, Berry GJ, et al. Pneumocystis carinii pneumonia : CT and HRCT observations. J Comput Assist Tomogr 1990 ; 14 : 756-9.
PubMed
8. Kanne JP, Yandow DR, Meyer CA. Pneumocystis jiroveci pneumonia : high-resolution CT findings in patients with and without HIV infection. Am J Roentgenol 2012 ; 198 : W555-61.
 
9. Hardak E, Brook O, Yigla M. Radiological features of Pneumocystis jirovecii Pneumonia in immunocompromised patients with and without AIDS. Lung 2010 ; 188 : 159-63.
PubMed
10. 徳田均. 非AIDS症例におけるニューモシスチス肺炎. 日胸 2010 ; 69 : 112-23.
Medical*Online
11. Tokuda H, Sakai F, Yamada H, et al. Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome : a multicenter study. Intern Med 2008 ; 47 : 915-23.
PubMed
12. Kameda H, Tokuda H, Sakai F, et al. Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents : importance of Pneumocystis pneumonia in Japan revealed by a multicenter study. Intern Med 2011 ; 50 : 305-13.
PubMed
13. Webb R, Muller NL, Naidich DP. Mosaic perfusion and mosaic attenuation. In : High resolution CT of the lung, 4th ed. Philadelphia : Lippinncott Williams & Wilkins, 2009 : 152-7.
 
14. Remy-Jardin M, Remy J, Cortet B, et al. Lung changes in rheumatoid arthritis : CT findings. Radiology 1994 ; 193 : 375-82.
PubMed
15. Mori S, Koga Y, Sugimoto M, et al. Comparison of pulmonary abnormalities on high-resolution computed tomography in patients with early versus longstanding rheumatoid arthritis. J Rheumatol 2008 ; A35 : 1513-21.
 
16. Mori S, Koga Y, Sugimoto M. Small airway obstruction in patients with rheumatoid arthritis. Mod Rheumatol 2011 ; 21 : 164-73.
PubMed
17. Tasaka S, Tokuda H, Sakai F, et al. Comparison of clinical and radiological features of Pneumocystis pneumonia between malignancy cases and acquired immunodeficiency syndrome cases : a multicenter study. Intern Med 2010 ; 49 : 273-81.
 
18. Torres HA, Chemaly RF, Storey R, et al. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients. Eur J Clin Microbiol Infect Dis 2006 ; 25 : 382-8.
PubMed
P.54 掲載の参考文献
1. Hughes WT, McNabb PC, Makres TD, et al. Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother 1974 ; 5 : 289-93.
PubMed
2. Hughes WT, Feldman S, Sanyal SK. Treatment of Pneumocystis carinii pneumonitis with trimethoprim-sulfamethoxazole. Can Med Assoc J 1975 ; 112 : 47-50.
PubMed
3. Green H, Paul M, Vidal L, et al. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients : systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007 ; 82 : 1052-9.
PubMed
4. Winston DJ, Lau Wk, Gale RP, et al. Trimethoprim-sulfamethoxazole for the treatment of Pneumocystis carinii pneumonia. Ann Intern Med 1980 ; 92 : 762-9.
PubMed
5. Young LS, Trimethoprim-sulfamethoxazole in the treatment of adults with pneumonia due to Pneumocystis carinii. Rev Infect Dis 1982 ; 4 : 608-13.
PubMed
6. Sattler FR, Cowan R, Nielsen DM, et al. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Ann Intern Med 1988 ; 109 : 280-7.
PubMed
7. Thomas M, Rupali P, Woodhouse A, et al. Good outcome with trimethoprim 10mg/kg/daysulfamethoxazole 50mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients. Scand J Infect Dis 2009 ; 41 : 862-8.
 
8. Mitsuyasu RT, Corwin HL, Harris AA, et al. Failure of trimethoprim-sulfamethoxazole in the therapy of recurrent Pneumocystis carinii pneumonia. Am Rev Respir Dis 1982 ; 125 : 762-5.
PubMed
9. Ma L, Borio L, Masur H, et al. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J Infect Dis 1999 ; 180 : 1969-78.
PubMed
10. Takahashi T, Endo M, Nakamura T, et al. Dihydrofolate reductase gene polymorphisms in Pneumocystis carinii f. sp. hominis in Japan. J Med Microbiol 2002 ; 51 : 510-5.
 
11. Nahimana A, Rabodonirina M, Bille J, et al. Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis. Antimicrob Agents Chemother 2004 ; 48 : 4301-5.
PubMed
12. Helweg-Larsen J, Benfield TL, Eugen-Olsen J, et al. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet 1999 ; 354 : 1347-51.
PubMed
13. Takahashi T, Hosoya N, Endo T, et al., Relationship between mutations in dihydropteroate synthase of Pneumocystis carinii f. sp. hominis isolates in Japan and resistance to sulfonamide therapy. J Clin Microbiol 2000 ; 38 : 3161-4.
PubMed
14. Navin TR, Bread CB, Huang L, et al. Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P. carinii pneumonia in patients with HIV-1 : a prospective study. Lancet 2001 ; 358 : 545-9.
 
P.60 掲載の参考文献
1. Conte JE Jr, Chernoff D, Feigal DW Jr, et al. Intravenous or inhaled pentamidine for treating Pneumocystis carinii pneumonia in AIDS. A randomized trial. Ann Intern Med 1990 ; 113 : 203-9.
PubMed
2. Arasteh KN, Vohringer HF, Heise WS, et al. Pentamidine aerosol vs cotrimoxazole in the treatment of slight to moderate Pneumocystis carinii pneumonia. Drug Invest 1994 ; 8 : 321-30.
 
3. Montgomery AB, Feigal DW Jr, Sattler F, et al. Pentamidine aerosol versus trimethoprimsulfamethoxazole for Pneumocystis carinii in acquired immune deficiency syndrome. Am J Respir Crit Care Med 1995 ; 151 : 1068-74.
 
4. Wharton JM, Coleman DL, Wofsy CB, et al. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann Intern Med 1986 ; 105 : 37-44.
PubMed
5. Klein NC, Duncanson FP, Lenox TH, et al. Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients : results of a large prospective randomized treatment trial. AIDS 1992 ; 6 : 301-5.
PubMed
6. Sattler FR, Cowan R, Nielsen DM, et al. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Ann Intern Med 1988 ; 109 : 280-7.
PubMed
7. 医薬品インタビューフォーム. カリニ肺炎治療薬. ベナンバックス(R) 注用300mg, p20.
 
8. Hughes W, Leoung G, Kramer F, et al. Comparison of atovaquone (566C80) with trimethoprimsulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 1993 ; 328 : 1521-7.
 
9. Dohn MN, Weinberg WG, Torres RA, et al. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Ann Intern Med 1994 ; 121 : 174-80.
PubMed
10. 医薬品インタビューフォーム. ニューモシスチス肺炎治療薬. サムチレール内容懸濁液 15%, p32.
 
11. Safrin S, Finkelstein DM, Feinberg J, et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med 1996 ; 124 : 792-802.
 
12. Medina I, Mills J, Leoung G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med 1990 ; 323 : 776-82.
PubMed
13. Toma E, Fournier S, Dumont M, et al. Clindamycin/primaquine versus trimethoprimsulfamethoxazole as primary therapy for Pneumocystis carinii pneumonia in AIDS : a randomized, double-blind pilot trial. Clin Infect Dis 1993 ; 17 : 178-84.
 
14. Safrin S, Finkelstein DM, Feinberg J, et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med 1996 ; 124 : 792-802.
 
15. Powles MA, Liberator P, Anderson J, et al. Efficacy of MK-991 (L-743, 872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemo 1998 ; 42 : 1985-9.
 
16. Annaloro C, Della Volpe A, Usardi P, et al. Caspofungin treatment of Pneumocystis pneumonia during conditioning for bone marrow transplantation. Eur J Clin Microbiol Infect Dis 2006 ; 25 : 52-4.
PubMed
17. Xiang-dong M, Cheng-li Q, Bing HE, et al. Caspofungin in salvage treatment of severe pneumocystis pneumonia : case report and literature review. Chin Med J 2009 ; 122 : 996-9.
 
18. Utili R, Durante-Mangoni E, Basilico C, et al. Efficacy of caspofungin addition to trimethoprimsulfamethoxazole treatment for severe Pneumocystis pneumonia in solid organ transplant recipients. Transplantation 2007 ; 84 : 685-8.
 
P.67 掲載の参考文献
1. Catherinot E, Lanternier F, Bougnoux ME, et al. Pneumocystis jirovecii Pneumonia. Infect Dis Clin North Am 2010 ; 24 : 107-38.
PubMed
2. Curtis JR, Yarnold PR, Schwartz DN, et al. Improvements in outcomes of acute respiratory failure for patients with human immunodeficiency virus-related Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 2000 ; 162 : 393-8.
PubMed
3. Thomas CF Jr, Limper AH. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol 2007 ; 5 : 298-308.
PubMed
4. Huang L, Morris A, Limper H, et al. An official ATS Workshop Summary : recent advances and future directions in Pneumocystis pneumonia (PCP). Prc Am Thorac Soc 2006 ; 3 : 655-64.
 
5. 徳田均. ニューモシスチス : 過剰生体応答 ; 急性肺障害. 呼吸器内科 2011 ; 19 : 37-44.
 
6. Azoulay E, Parrot A, Flahault A, et al. AIDS-related Pneumocystis carinii pneumonia in the era of adjunctive steroids : implication of BAL neutrophilia. Am J Respir Crit Care Med 1999 ; 160 : 493-9.
PubMed
7. Benfield TL, Vestbo J, Junge J, et al Prognostic value of interleukin-8 in AIDS-associated Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1995 ; 151 : 1058-62.
PubMed
8. Travis WD, Pittaluga S, Lipschik GY, et al. Atypical pathological manifestations of Pneumocystis carinii pneumonia in the acquired immune deficiency syndrome. Review of 123 lung biopsies from 76 patients with emphasis of cysts, vascular invasion, vasculitis and granulomas. Am J Surg Pathol 1990 ; 14 : 615-25.
PubMed
9. Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome. The National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia. N Engl J Med 1990 ; 323 : 1500-4.
 
10. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Recommendations of the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the HIV Medicine Association of the Infectious Diseases Society of America (HIVMA/IDSA). MMWR 2009 ; 58 : 1-198. (http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5804a1.htm)
 
11. Briel M, Bucher H, Boscacci R, et al. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection. Cochrane Summaries Jan. 21, 2009 (http://summaries.cochrane.org/CD006150/).
 
12. Walmsley S, Levinton C, Brunton J, et al. A multicenter randomized double-blind placebo-controlled trial of adjunctive corticosteroids in the treatment of Pneumocystis carinii pneumonia complicating the acquired immune deficiency syndrome. J Acquir Immune Defic Syndr Hum Retrovirol 1995 ; 8 : 348-57.
 
13. Nielsen TL, Eeftinck Schattenkerk JK, Jensen BN, et al. Adjunctive corticosteroid therapy for Pneumocystis carinii pneumonia in AIDS : a randomized European multicenter open label study. J Acquir Immune Defic Syndr 1992 ; 7 : 726-31.
PubMed
14. Limper AH, Offord KP, Smith TF, et al. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989 ; 140 : 1204-9.
PubMed
15. 徳田均. 非AIDS症例におけるニューモシスチス肺炎. 日胸 2010 ; 69 : 112-23.
Medical*Online
16. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 1998 ; 113 : 1215-24.
PubMed
17. Delclaux C, Zahar JR, Amraoui G, et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus-infected patients : retrospective study of 31 patients. Clin Infect Dis 1999 ; 29 : 670-2.
PubMed
18. Roblot F, Le Moal G, Godet C, et al. Pneumocystis carinii pneumonia in patients with hematologic malignancies : a descriptive study. J Infect 2003 ; 47 : 19-27.
 
19. Moon SM, Kim T, Kim YS, et al. Outcomes of moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients. Antimicrob Agents Chemother 2011 ; 55 : 4613-8.
PubMed
20. Tasaka S, Kobayashi S, Kamata H, et al. Cytokine profiles of bronchoalveolar lavage fluid in patients with pneumocystis pneumonia. Microbiol Immunol 2010 ; 54 : 425-33.
PubMed
21. Tokuda H, Sakai F, Yamada H, et al. Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome : a multicenter study. Intern Med 2008 ; 47 : 915-23.
PubMed
22. Kameda H, Tokuda H, Sakai F, et al. Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents : importance of Pneumocystis pneumonia in Japan revealed by a multicenter study. Intern Med 2011 ; 50 : 305-13.
PubMed
23. Thomas CF, Limper AH. Treatment and prevention of Pneumocystis pneumonia in non-HIVinfected patients. (http://www.uptodate.com/contents/treatment-and-prevention-of-pneumocystispneumonia-in-non-hiv-infected-patients)
 
P.72 掲載の参考文献
1. Masip J, Roque M, Sanchez B, et al. Noninvasive ventilation in acute cardiogenic pulmonary edema : systematic review and meta-analysis. JAMA 2005 ; 294 : 3124-30.
PubMed
2. Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome : the Berlin Definition. JAMA 2012 ; 307 : 2526-33.
PubMed
3. Antonelli M, Conti G, Esquinas A, et al. A multiple-center survey on the use in clinical practice of noninvasive ventilation as a first-line intervention for acute respiratory distress syndrome. Crit Care Med 2007 ; 35 : 18-25.
PubMed
4. Barbier F, Coquet I, Legriel S, et al. Etiologies and outcome of acute respiratory failure in HIVinfected patients. Intensive Care Med 2009 ; 35 : 1678-86.
 
5. Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004 ; 350 : 2487-98.
PubMed
6. Catherinot E, Lanternier F, Bougnoux ME, et al. Pneumocystis jirovecii Pneumonia. Infect Dis Clin North Am 2010 ; 24 : 107-38.
PubMed
7. Mansharamani NG, Garland R, Delaney D, et al. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995 : comparison of HIV-associated cases to other immunocompromised states. Chest 2000 ; 118 : 704-11.
PubMed
8. Wang Z, Foye A, Chang Y, et al. Inhibition of surfactant activity by Pneumocystis carinii organisms and components in vitro. Am J Physiol Lung Cell Mol Physiol 2005 ; 288 : L1124-31.
PubMed
9. Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med 2013 ; 41 : 263-306.
PubMed
P.79 掲載の参考文献
1. Stansell JD, Osmond DH, Charlebois E, et al. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1997 ; 155 : 60-6.
 
2. Masur H, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U. S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002 ; 137 : 435-78.
 
3. Center for International Blood and Marrow Transplant Research (CIBMTR), National Marrow Donor Program (NMDP), European Blood and Marrow Transplnt Group (EBMT). Guidelines for preventing infectious complications among hematopoietic cell transplant recipients : a global perspective. Bone Marrow Transplant 2009 ; 44 : 453-558.
PubMed
4. National Comprehensive Cancer Network. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections. Version 1. 2013 (Accessed on May 03, 2013).
 
5. Martin SI, Fishman JA. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant 2009 ; 9 : S227-33.
PubMed
6. Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis 2001 ; 33 : 1397-405.
PubMed
7. Kidney Disease : Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009 ; 9 : S1-155.
PubMed
8. Tolaney SM, Partridge AH, Sheib RG, et al. Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer. J Clin Oncol 2006 ; 24 : 5330-1.
PubMed
9. Velcheti V, Govindan R. Pneumocystis pneumonia in a patient with non-small cell lung cancer (NSCLC) treated with pemetrexed containing regimen. Lung Cancer 2007 ; 57 : 240-2.
 
10. Yoon SY, Ki HK, Kim SY, et al. Pneumocystis carinii pneumonia in gastric cancer patients without acquired immune deficiency syndrome : 3 cases report and literature review. J Korean Surg Soc 2012 ; 83 : 50-5.
PubMed
11. Saito Y, Nagayama M, Miura Y, et al. A case of pneumocystis pneumonia associated with everolimus therapy for renal cell carcinoma. Jpn J Clin Oncol 2013 ; 43 : 559-62.
PubMed
12. Lehman JS, Kalaaji AN. Role of primary prophylaxis for pneumocystis pneumonia in patients treated with systemic corticosteroids or other immunosuppressive agents for immune-mediated dermatologic conditions. J Am Acad Dermatol 2010 ; 63 : 815-23.
PubMed
13. 田中良哉, ほか. 免疫疾患の既存治療法の評価とその合併症に関する研究 (H17-免疫-一般-012) http://www.allergy.go.jp/Research/Shouroku_03/18_tanaka_01.html (accsessed on May 05, 2013).
 
14. Kadoya A, Okada J, Iikuni Y, et al. Risk factors for P neumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus. J Rheumatol 1996 ; 23 : 1186-8.
PubMed
15. Green H, Paul M, Vidal L, et al. Prophylaxis for Pne umocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2007 : CD005590.
 
16. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy : results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006 ; 54 : 2368-76.
PubMed
17. Koike T, Harigai M, Ishiguro N, et al. Safety and effectiv eness of adalimumab in Japanese rheumatoid arthritis patients : postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol 2012 ; 22 : 498-508.
 
18. Takeuchi T, Tatsuki Y, Nagami Y, et al. Postmarketing su rveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008 ; 67 : 189-94.
 
19. Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 2009 ; 36 : 898-906.
PubMed
20. Carmona EM, Limper AH. Update on the diagnosis and treatment of Pneumocystis pneumonia. Ther Adv Respir Dis 2011 ; 5 : 41-59.
PubMed
21. Limper AH, Knox KS, Sarosi GA, et al. An official American Thoracic Society statement : treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011 ; 183 : 96-128.
PubMed
22. Sepkowitz KA. Opportunistic infecti ons in patients with and patients without Acquired Immunodeficiency Syndrome. Clin Infect Dis 2002 ; 34 : 1098-107.
 
23. Huang L, Morris A, Limper AH, et al. An Official ATS Workshop Summary : recent advances and future directions in pneumocystis pneumonia (PCP). Proc Am Thorac Soc 2006 ; 3 : 655-64.
PubMed
24. Sepkowitz KA, Brown AE, Armstrong D. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. More patients, same risk. Arch Intern Med 1995 ; 155 : 1125-8.
PubMed
25. Thomas CF Jr, Limper AH. Pne umocystis pneumonia. N Engl J Med 2004 ; 350 : 2487-98.
 
26. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome : associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996 ; 71 : 5-13.
PubMed
27. Sepkowitz KA, Brown AE, Telzak EE, et al. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 1992 ; 267 : 832-7.
 
28. Hughes WT, Rivera GK, Schell MJ, et al. Successful inter mittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1987 ; 316 : 1627-32.
 
29. Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988 ; 259 : 1185-9.
PubMed
30. Schneider MM, Nielsen TL, Nelsing S, et al. Efficacy and toxicity of two doses of trimethoprimsulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus. Dutch AIDS Treatment Group. J Infect Dis 1995 ; 171 : 1632-6.
 
31. Lindemulder S, Albano E. Successful intermittent prophylaxis with trimethoprim/sulfamethoxazole 2 days per week for Pneumocystis carinii (jiroveci) pneumonia in pediatric oncology patients. Pediatrics 2007 ; 120 : e47-51.
PubMed
32. El-Sadr WM, Luskin-Hawk R, Yurik TM, et al. A randomized tr ial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Clin Infect Dis 1999 ; 29 : 775-83.
 
33. Podzamczer D, Salazar A, Jimenez J, et al. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med 1995 ; 122 : 755-61.
PubMed
34. Saah AJ, Hoover DR, Peng Y, et al. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study. JAMA 1995 ; 273 : 1197-202.
PubMed
35. Vasconcelles MJ, Bernardo MV, King G, et al. Aerosolize d pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant 2000 ; 6 : 35-43.
 
36. Schneider MM, Hoepelman AI, Eeftinck Schattenkerk JK, et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. N Engl J Med 1992 ; 327 : 1836-41.
PubMed
37. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. N Engl J Med 1992 ; 327 : 1842-8.
PubMed
38. Ioannidis JP, Cappelleri JC, Skolnik PR, et al. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 1996 ; 156 : 177-88.
PubMed
39. Warnock AC, Rimland D. Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia. Pharmacotherapy 1996 ; 16 : 1030-8.
PubMed
40. Hughes WT. Use of dapsone in the pr evention and treatment of Pneumocystis carinii pneumonia : a review. Clin Infect Dis 1998 ; 27 : 191-204.
 
41. Chan C, Montaner RL, Lefebre EA, et al. Atovaquone suspensio n compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis 1999 ; 180 : 369-76.
PubMed
42. El-Sadr WM, Murphy RL, Yurik TM, et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N Engl J Med 1998 ; 339 : 1889-95.
PubMed
43. Colby C, McAfee S, Sackstein R, et al. A prospective rando mized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999 ; 24 : 897-902.
 
44. Kaplan JE, Hanson DL, Navin TR, et al. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States : reassessment of indications for chemoprophylaxis. J Infect Dis 1998 ; 178 : 1126-32.
PubMed
45. Weverling GJ, Mocroft A, Ledergerber B, et al. Discontinuati on of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet 1999 ; 353 : 1293-8.
 
46. Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med 1999 ; 340 : 1301-6.
 
47. D'Egidio GE, Kravcik S, Cooper CL, et al. Pneumocystis j iroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed. AIDS 2007 ; 21 : 1711-5.
 
P.88 掲載の参考文献
1. Le Gal S, Damiani C, Rouille A, et al. A cluster of Pneumocystis infections among renal transplant recipients : molecular evidence of colonized patients as potential infectious sources of Pneumocystis jirovecii. Clin Infect Dis 2012 ; 54 : e62-71.
PubMed
2. Olsson M, Eriksson B, Elvin K, et al. Genotypes of clustered cases of Pneumocystis carinii pneumonia. Scand J Infect Dis 2001 ; 33 : 285-9.
PubMed
3. Rabodonirina M, Vanhems P, Couray-Targe S, et al. Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalized with HIV-infected patients. Emerg Infect Dis 2004 ; 10 : 1766-73.
PubMed
4. Hocker B, Wendt C, Nahimana A, et al. Molecular evidence of Pneumocystis transmission in pediatric transplant unit. Emerg Infect Dis 2005 ; 11 : 330-2.
PubMed
5. de Boer M, Bruijnesteijn van Coppenraet L, Gaasbeek A, et al. An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients : interhuman transmission or a common environmental source? Clin Infect Dis 2007 ; 44 : 1143-9.
PubMed
6. Schmoldt S, Schuhegger R, Wendler T, et al. Molecular evidence of nosocomial Pneumocystis jirovecii transmission among 16 patients after kidney transplantation. J Clin Microbiol 2008 ; 46 : 966-71.
PubMed
7. Yazaki H, Goto N, Uchida K, et al. Outbreak of Pneumocystis jiroveci pneumonia in renal transplant recipients : P. jiroveci is contagious to the susceptible host. Transplantation 2009 ; 88 : 380-5.
 
8. Gianella S, Haeberli L, Joos B, et al. Molecular evidence of interhuman transmission in an outbreak of Pneumocystis jirovecii p neumonia among renal transplant recipients. Transpl Infect Dis 2010 ; 12 : 1-10.
 
9. Helweg-Larsen J, Tsolaki A, Miller R, et al. Clusters of Pneumocystis carinii pneumonia : analysis of person-to-person transmission by genotyping. QJM 1998 ; 91 : 813-20.
PubMed
10. Lundgren B, Elvin K, Rothman LP, et al. Transmission of Pneumocystis carinii from patients to hospital staff. Thorax 1997 ; 52 : 422-4.
PubMed
11. Miller RF, Ambrose HE, Wakefield AE. Pneumocystis carinii f. sp. hominis DNA in immunocompetent health care workers in contact with patients with P. carinii pneumonia. J Clin Microbiol 2001 ; 39 : 3877-82.
 
12. Matsumura Y, Shindo Y, Iinuma Y, et al. Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotype s. BMC Infect Dis 2011 ; 11 : 76.
 
13. Esteves F, Montes-Cano M, de la Horra C, et al. Pneumocystis jirovecii multilocus genotyping profiles in patients from Portugal and Spain. Clin Microbiol Infect 2008 ; 14 : 356-62.
PubMed
14. Beser J, Hagblom P, Fernandez V. Frequent in vit ro recombination in internal transcribed spacers 1 and 2 during genotyping of Pneumocystis jirovecii. J Clin Microbiol 2007 ; 45 : 881-6.
 
15. Nevez G, Chabe M, Rabodonirina M, et al. Nosocomial Pneumoc ystis jirovecii infections. Parasite 2008 ; 15 : 359-65.
 
16. Choukri F, Menotti J, Sarfati C, et al. Quantification and spread of Pneumocystis jirovecii in the surrounding air of patients with Pneumocystis pneumonia. Clin Infect Dis 2010 ; 51 : 259-65.
PubMed
17. Morris A, Wei K, Afshar K, et al. Epidemiology and clinical significance of pneumocystis colonization. J Infect Dis 2008 ; 197 : 10-7.
PubMed
18. Calderon EJ, Rivero L, Respaldiza N, et al. Systemic inflammation in patients with chronic obstructive pulmonary disease who are colonized with Pneumocystis jiroveci. Clin Infect Dis 2007 ; 45 : e17-9.
PubMed
19. Ponce CA, Gallo M, Bust amante R, et al. Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population. Clin Infect Dis 2010 ; 50 : 347-53.
 
20. Vargas SL, Pon ce CA, Galvez P, et al. Pneumocystis is not a direct cause of sudden infant death syndrome. Pediatr Infect Dis J 2007 ; 26 : 81-3.
 
21. Gutierrez S, Morilla R, Leon JA, et al. High prevalence of Pneumocystis jiro veci colonization among young HIV-infected patients. J Adolesc Health 2011 ; 48 : 103-5.
 
22. Dumoulin A, Mazars E, Seguy N, et al. Transmission of Pneumocystis carinii disease from immunocompetent contac ts of infected hosts to susceptible hosts. Eur J Clin Microbiol Infect Dis 2000 ; 19 : 671-8.
 
23. Gigliotti F, Harmsen AG, Wright TW. Characterization of transmission of Pneumocystis ca rinii f. sp. muris through immunocompetent BALB/c mice. Infect Immun 2003 ; 71 : 3852-6.
 
24. de Boer MG, Bruijnesteijn van Coppenraet LE, Gaasbeek A, et al. An outbreak of Pneumocystis jirov eci pneumonia with 1 predominant genotype among renal transplant recipients : interhuman transmission or a common environmen tal source? Clin Infect Dis 2007 ; 44 : 1143-9.
 
25. Morris A, Norris KA. Colonization by Pneumocystis jirovecii and its role in disease. Clin Microbiol Rev 2012 ; 25 : 297-317.
PubMed
26. Totet A, Latou che S, Duwat H, et al. Multilocus genotyping of Pneumocystis jirovecii in patients developing diverse forms of parasitism : implication for a w ide human reservoir for the fungus. J Eukaryot Microbiol 2003 ; 50 Suppl : 670-1.
 
27. Goto N, Oka S. Pneumocystis jirovecii pneumonia in kidney transplantation. Transpl Infect Dis 2011 ; 13 : 551-8.
PubMed
28. Mori S, Sugimoto M. Pneumocystis jirovecii infection : an emerging threat to patients with rheumatoid arthritis. Rheumatology (Oxford) 2012 ; 51 : 2120-30.
PubMed

[II] 各論

P.96 掲載の参考文献
1. Kovacs JA, Gill VJ, Meshnick S, et al. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA 2001 ; 286 : 2450-60.
PubMed
2. Phair J, Munoz A, Detels R, et al. The risk of Pn eumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med 1990 ; 322 : 161.
 
3. Centers for Disease Control and Prevention. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1989 ; 38 : 1-9.
 
4. Kaplan JE, Hanson D, Dworkin MS, et al. Epide-miology of human immunodeficiency virusassociated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000 ; 30 : S5-S14.
 
5. Buchacz K, Baker RK, Palella FJ Jr, et al. AIDS-defining opportunistic illnesses in US patients, 1994-2007 : a cohort study. AIDS 2010 ; 24 : 1549-59.
PubMed
6. Lindegren ML, Byers B, Rogers M, et al. On the verge of elimination of perinatally acquired HIV/AIDS? Updated trends in HIV/AIDS in the United States [abstract 228]. In : Alexandria VA. Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections. Foundation for Retrovirology and Human Health, 1999 : 111.
 
7. Nesheim SR, Kapogiannis BG, Soe MM, et al. Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004. Pediatrics 2007 ; 120 : 100-9.
PubMed
8. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study : an observational study. Lancet 2003 ; 362 : 22-9.
PubMed
9. Malin AS, Gwanzura LK, Klein S, et al. Pneumocystis carinii pneumonia in Zimbabwe. Lancet 1995 ; 346 : 1258-61.
PubMed
10. Worodria W, Okot-Nwang M, Yoo SD, et al. Int Causes of lower respiratory infection in HIV-infected Ugandan adults who are sputum AFB smear-negative. J Tuberc Lung Dis 2003 ; 7 : 117-23.
PubMed
11. 厚生労働省エイズ動向委員会平成23 (2011) 年エイズ発生動向年報 (http://api-net.jfap.or.jp/status/2011/11nenpo/nenpo_menu.htm).
 
12. 安岡彰, 塚本美鈴, 小佐井康介, ほか. 平成24年度厚生労働科学研究費補助金エイズ対策研究事業「HIV感染症に伴う日和見合併症の全国調査2011年-全国HIV診療拠点病院アンケート調査-」.
 
13. Grant PM, Komarow L, Andersen J, et al. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS One 2010 ; 5 : e11416.
 
14. Achenbach CJ, Harrington RD, Dhanireddy S, et al. Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection. Clin Infect Dis 2012 ; 54 : 424-33.
PubMed
P.102 掲載の参考文献
1. Stansell JD, Osmond DH, Charlebois E, et al. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1997 ; 155 : 60-6.
 
2. Fujii T, Nakamura T, Iwamoto A. Pneumocystis pneumonia in patients with HIV infection : clinical manifestations, laboratory findings, and radiological features. J Infect Chemother 2007 ; 13 : 1-7.
PubMed
3. Kovacs JA, Masur H. Evolving health effects of Pneumocystis : one hundred years of progress in diagnosis and treatment. JAMA 2009 ; 301 : 2578-85.
PubMed
4. Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004 ; 350 : 2487-98.
PubMed
5. Levine SJ. Pneumocystis carinii. Clin Chest Med 1996 ; 17 : 665-95.
PubMed
6. Tasaka S, Tokuda H. Recent advances in the diagnosis of Pneumocystis jirovecii pneumonia in HIV-infected adults. Expert Opin Med Diagn 2013 ; 7 : 85-97.
 
7. Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia : a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984 ; 100 : 663-71.
PubMed
8. Limper AH, Offord KP, Smith TF, et al. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989 ; 140 : 1204-9.
PubMed
9. Mayor B, Schnyder P, Giron J, et al. Mediastinal and hilar lymphadenopathy due to Pneumocystis carinii infection in AIDS patients : CT features. J Comput Assist Tomogr 1994 ; 18 : 408-11.
PubMed
10. Zaman MK, White DA. Serum lactate dehydrogenase levels and Pneumocystis carinii pneumonia. Diagnostic and prognostic significance. Am Rev Respir Dis 1988 ; 137 : 796-800.
PubMed
11. Vogel M, Weissgerber P, Goeppert B, et al. Accuracy of serum LDH elevation for the diagnosis of Pneumocystis jiroveci pneumonia. Swiss Med Wkly 2011 ; 141 : w13184.
 
12. Desmet S, Van Wijngaerden E, Maertens J, et al. Serum (1-3) -beta-D-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J Clin Microbiol 2009 ; 47 : 3871-4.
PubMed
13. Watanabe T, Yasuoka A, Tanuma J, et al. Serum (1→3) beta-D-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis 2009 ; 49 : 1128-31.
 
14. Held J, Koch M, Reischl U, et al. Serum (1→3) -beta-D-Glucan measurement as early indicator for Pneumocystis jirovecii pneumonia and evaluation of its prognostic value. Clin Microbiol Infect 2011 ; 17 : 595-602.
 
15. de Boer MG, Gelinck LB, van Zelst BD, et al. beta-d-Glucan and S-adenosylmethionine serum levels for the diagnosis of Pneumocystis pneumonia in HIV-negative patients : a prospective study. J Infect 2011 ; 62 : 93-100.
 
16. Tasaka S, Hasegawa N, Kobayashi S, et al. Serum indicators for the diagnosis of pneumocystis pneumonia. Chest 2007 ; 131 : 1173-80.
 
17. Sax PE, Komarow L, Finkelman MA, et al. Blood (1→3) -beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia. Clin Infect Dis 2011 ; 53 : 197-202.
 
18. Onishi A, Sugiyama D, Kogata Y, et al. Diagnostic accuracy of serum 1, 3-beta-D-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis : systematic review and meta-analysis. J Clin Microbiol 2012 ; 50 : 7-15.
PubMed
19. Karageorgopoulos DE, Qu JM, Korbila IP, et al. Accuracy of beta-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia : a meta-analysis. Clin Microbiol Infect 2013 ; 19 : 39-49.
 
20. Costa JM, Botterel F, Cabaret O, et al. Association between circulating DNA, serum (1→3) -beta-D-glucan, and pulmonary fungal burden in Pneumocystis pneumonia. Clin Infect Dis 2012 ; 55 : e5-8.
 
21. Koga M, Koibuchi T, Kikuchi T, et al. Kinetics of serum beta-D-glucan after Pneumocystis pneumonia treatment in patients with AIDS. Intern Med 2011 ; 50 : 1397-401.
PubMed
22. Skelly M, Hoffman J, Fabbri M, et al. S-adenosylmethionine concentrations in diagnosis of Pneumocystis carinii pneumonia. Lancet 2003 ; 361 : 1267-8.
PubMed
23. Takahashi T, Ebihara Y, Manabe A, et al. Surfactant protein D and KL-6 as serologic indicators of Pneumocystis carinii pneumonia in a child with acute lymphoblastic leukemia. J Med 2001 ; 32 : 41-51.
 
24. Safrin S. New developments in the management of Pneumocystis carinii disease. AIDS Clin Rev 1993 : 95-112.
PubMed
25. Lu Y, Ling G, Qiang C, et al. PCR diagnosis of Pneumocystis pneumonia : a bivariate metaanalysis. J Clin Microbiol 2011 ; 49 : 4361-3.
 
26. Larsen HH, Huang L, Kovacs JA, et al. A prospective, blinded study of quantitative touch-down polymerase chain reaction using oral-wash samples for diagnosis of Pneumocystis pneumonia in HIV-infected patients. J Infect Dis 2004 ; 189 : 1679-83.
PubMed
27. de Oliveira A, Unnasch TR, Crothers K, et al. Performance of a molecular viability assay for the diagnosis of Pneumocystis pneumonia in HIV-infected patients. Diagn Microbiol Infect Dis 2007 ; 57 : 169-76.
 
28. Morris A, Wei K, Afshar K, et al. Epidemiology and clinical significance of pneumocystis colonization. J Infect Dis 2008 ; 197 : 10-7.
PubMed
P.109 掲載の参考文献
1. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men : evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981 ; 305 : 1425-31.
PubMed
2. Masur H, Michelis MA, Greene JB, et al. An outbreak of community-acquired Pneumocystis carinii pneumonia : initial manifestation of cellular immune dysfunction. N Engl J Med 1981 ; 305 : 1431-8.
PubMed
3. Oh MD, Park SW, Kim HB, et al. Spectrum of opportunistic infections and malignancies in patients with human immunodeficiency virus infection in South Korea. Clin Infect Dis 1999 ; 29 : 1524-8.
PubMed
4. Yoshizawa S, Yasuoka A, Kikuchi Y, et al. A 5-day course of oral desensitization to trimethoprim/sulfamethoxazole (T/S) in patients with human immunodeficiency virus type-1 infection who were previously intolerant to T/S. Ann Allergy Asthma Immunol 2000 ; 85 : 241-4.
 
5. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents : recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/0 (2013年5月7日参照)
 
6. Montaner JS, Lawson LM, Levitt N, et al. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990 ; 113 : 14-20.
PubMed
7. Bozzette SA, Sattler FR, Chiu J, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990 ; 323 : 1451-7.
 
8. Gagnon S, Boota AM, Fischl MA, et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990 ; 323 : 1444-50.
PubMed
9. Harrison's principles of internal medicine, 18th ed. McGraw-Hill, 2011 : 1671-4.
 
10. Mandell, Douglas, and Bennett's principles and practice of infectious diseases, 7th ed. 129 management of opportunistic infections associated with human immunodeficiency virus infection. Churchill Livingstone, 2009 : 1858-74
 
11. The Sanford guide to antimicrobial therapy 2011, 41st ed. Antimicrobial Therapy 2011 : 83, 135, 142.
 
12. 国立国際医療センターエイズ治療・研究開発センター. HIV感染症とその合併症診断と治療ハンドブック (第2版). 2006 : 66.
 
13. Koval CE, Gigliotti F, Nevins D, et al. Immune reconstitution syndrome after successful treatment of Pneumocystis carinii pneumonia in a man with human immunodeficiency virus type 1 infection. Clin Infect Dis 2002 ; 35 : 491-3.
 
14. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections : a multicenter randomized strategy trial. PLoS ONE 2009 ; 4 : e5575.
PubMed
P.113 掲載の参考文献
1. Radhi S, Alexander T, Ukwu M, et al. Outcome of HIV-associated Pneumocystis pneumonia in hospitalized patients from 2000 through 2003. BMC Infect Dis 2008 ; 8 : 118.
PubMed
2. Walzer PD, Evans HE, Copas AJ, et al. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients : 1985-2006. Clin Infect Dis 2008 ; 46 : 625-33.
PubMed
3. Fei MW, Kim EJ, Sant CA, et al. Predicting mortality from HIV-associated Pneumocyctis pneumonia at illness presentation : an observational cohort study. Thorax 2009 ; 64 : 1070-6.
 
4. Armstrong-James D, Copas AJ, Walzer PD, et al. A prognostic scoring tool for identification of patients at high and low risk of death from HIV-associated Pneumocyctis jirovecii pneumonia. Int J STD AIDS 2011 ; 22 : 628-34.
 
5. Lee CH, Helweg-Larsen J, Tang X, et al. Update on Pneumocystis carinii f. sp. hominis typing based on nucleotide sequence variations in internal transcribed spacer regions of rRNA genes. J Clin Microbiol 1998 ; 36 : 734-41.
PubMed
6. Nimri LF, Moura I, Huang L, et al. Genetic Diversity of Pneumocystis carinii f. sp. hominis based on variations in nucleotide sequences of internal transcribed spacers of rRNA genes. J Clin Microbiol 2002 ; 40 : 1146-51.
PubMed
7. Miller RF, Wakefield AE. Pneumocystis carinii genotypes and severity of pneumonia. Lancet 1999 ; 353 : 2039-40.
PubMed
8. van Hal SJ, Gilgado F, Doyle T, et al. Clinical significance and phylogenetic relationship of novel Australian Pneumocystis jirovecii genotypes. J Clin Microbiol 2009 ; 47 : 1818-23.
PubMed
9. Valerio A, Tronconi E, Mazza F, et al. Genotyping of Pneumocystis jiroveci pneumonia in Italian AIDS patients. Clinical outcome is influenced by dihydropteroate synthase and not by internal transcribed spacer genotype. J Acquir Immune Defic Syndr 2007 ; 45 : 521-8.
 
10. Helweg-Larsen J, Lee CH, Jin S, et al. Clinical correlation of variations in the internal transcribed spacer regions of rRNA genes in Pneumocystis carinii f. sp. hominis. AIDS 2001 ; 15 : 451-9.
PubMed
11. Nahimana A, Rabodonirina M, Bille J, et al. Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis. Antimicrob Agents Chemother 2004 ; 48 : 4301-5.
PubMed
12. Ma L, Borio L, Masur H, et al. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J Infect Dis 1999 ; 180 : 1969-78.
PubMed
13. Takahashi T, Endo T, Nakamura T, et al. Dihydrofolate reductase gene polymorphisms in Pneumocystis carinii f. sp. hominis in Japan. J Med Microbiol 2002 ; 51 : 510-5.
PubMed
14. Helweg-Larsen J, Benfield TL, Eugen-Olsen J, et al. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet 1999 ; 354 : 1347-51.
PubMed
15. Kazanjian P, Armstrong W, Hossler PA, et al. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. J Infect Dis 2000 ; 182 : 551-7.
PubMed
16. Rabodonirina M, Vaillant L, Taffe P, et al. Pneumocystis jirovecii genotype associated with increased death rate of HIV-infected patients with pneumonia. Emerg Infect Dis 2013 ; 19 : 21-8.
 
P.121 掲載の参考文献
1. Kaplan JE, Benson C, Holmes KK, et al. Guideline for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents : recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009 ; 58 : 1-207.
 
2. Kaplan JE, Hanson DL, Jones JL, et al. Viral load as an independent risk factor for opportunistic infections in HIV-infected adults and adolescents. AIDS 2001 ; 15 : 1831-6.
PubMed
3. Hirschtick RE, Glassroth J, Jordan MC, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N Engl J Med 1995 ; 333 : 845-51.
 
4. Schneider MM, Hoepelman AI, Eeftinck Schattenkerk JK, et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. N Engl J Med 1992 ; 327 : 1836-41.
PubMed
5. Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995 ; 332 : 693-9.
 
6. Schneider MM, Nielsen TL, Nelsing S, et al. Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus. Dutch AIDS Treatment Group. J Infect Dis 1995 ; 171 : 1632-6.
 
7. El-Sadr WM, Luskin-Hawk R, Yurik TM, et al. A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Clin Infect Dis 1999 ; 29 : 775-83.
PubMed
8. Cheung TW, Matta R, Neibart E, et al. Intramuscular pentamidine for the prevention of Pneumocystis carinii pneumonia in patients infected with human immunodeficiency virus. Clin Infect Dis 1993 ; 16 : 22-5.
PubMed
9. Kaplan JE, Hanson DL, Navin TR, et al. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States : reassessment of indications for chemoprophylaxis. J Infect Dis 1998 ; 178 : 1126-32.
PubMed
10. Weverling GJ, Mocroft A, Ledergerber B, et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet 1999 ; 353 : 1293-8.
 
11. D'Egidio GE, Kravcik S, Cooper CL, et al. Pnemocystic jirovecii pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/μl when viral replication is suppressed. AIDS 2007 ; 21 : 1711-5.
 
12. Chaiwarith R, Praparattanapan J, Nuntachit N, et al. Discontinuation of primary and secondary prophylaxis for oppotunistic infections in HIV-infected patients who had CD4+ cell count < 200 cells/mm3 but undetectable plasma HIV-1 RNA : an open-label randomized control trial. AIDS Patient Care STDS 2013 ; 27 : 71-6.
 
13. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. N Engl J Med 1992 ; 327 : 1842-8.
PubMed
14. Beumont MG, Graziani A, Ubel PA, et al. Safety of dapsone as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole. Am J Med 1996 ; 100 : 611-6.
PubMed
15. El-Sadr WM, Murphy RL, Yurik TM, et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N Engl J Med 1998 ; 339 : 1889-95.
PubMed
16. Ledergerber B, Mocroft A, Reiss P, et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med 2001 ; 344 : 168-74.
PubMed
17. Lopez Bernaldo de Quiros JC, Miro JM, Pena JM, et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. N Engl J Med 2001 ; 344 : 159-67.
PubMed
18. Solencky R. Drug desensitization. Immunol Allergy Clin North Am 2004 ; 24 : 425-43.
 
19. Choukri F, Menotti J, Sarfati C, et al. Quantification and spread of Pneumocystis jirovecii in the surrounding air of patients with pneumocystis pneumonia. Clin Infect Dis 2010 ; 51 : 259-65.
PubMed
20. Hernandez-Diaz S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000 ; 343 : 1608-14.
PubMed
21. Andersen DH. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics 1956 ; 18 : 614-24.
PubMed
22. Harstad TW, Little BB, Bawdon RE, et al. Embryofetal effects of pentamidine isethionate administered to pregnant Sprague-Dawley rats. Am J Obstet Gynecol 1990 ; 163 : 912-6.
PubMed
23. Dworkin MS, Williamson J, Jones JL, et al. Prophylaxis with trimethoprim-sulfamethoxazole for human immunodeficiency virus-infected patients : imapct on risk for infectious disease. Clin Infect Dis 2001 ; 33 : 393-8.
 
24. Czeizel AE, Rckenbauer M, Sorensen HT, et al. The teratorogenic risk of trimethoprim-sulfonamides : a population based-control study. Reporod Toxicol 2001 ; 15 : 637-46.
 
25. 平成23年エイズ発生動向年報. 厚生労働省エイズ動向委員会.
 
P.135 掲載の参考文献
1. Godeau B, Coutant-Perronne V, Le Thi Huong D, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease : report of 34 cases. J Rheumatol 1994 ; 21 : 246-51.
 
2. Sepkowitz KA. Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clin Infect Dis 2002 ; 34 : 1098-107.
PubMed
3. Kadoya A, Okada J, Iikuni Y, et al. Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus. J Rheumatol 1996 ; 23 : 1186-8.
PubMed
4. Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004 ; 17 : 770-82, table of contents.
 
5. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 1958 ; 2 : 265-70.
 
6. Hollander D, Manning RT. The use of alkylating agents in the treatment of Wegener's granulomatosis. Ann Intern Med 1967 ; 67 : 393-8.
PubMed
7. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis : an analysis of 158 patients. Ann Intern Med 1992 ; 116 : 488-98.
PubMed
8. Ognibene FP, Shelhamer JH, Hoffman GS, et al. Pneumocystis carinii pneumonia : a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med 1995 ; 151 : 795-9.
 
9. Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997 ; 40 : 2187-98.
 
10. Stegeman CA, Tervaert JW, de Jong PE, et al. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996 ; 335 : 16-20.
 
11. Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis 2001 ; 33 : 1397-405.
PubMed
12. Thomas CF, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004 ; 350 : 2487-98.
PubMed
13. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome : associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996 ; 71 : 5-13.
PubMed
14. Arend SM, Kroon FP, van't Wout JW. Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. An analysis of 78 cases. Arch Intern Med 1995 ; 155 : 2436-41.
 
15. Pryor BD, Bologna SG, Kahl LE. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 1996 ; 39 : 1475-82.
PubMed
16. Tashkin D, Elashoff R, Clements P, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006 ; 354 : 2655-66.
PubMed
17. Porges AJ, Beattie SL, Ritchlin C, et al. Patients with systemic lupus erythematosus at risk for Pneumocystis carinii pneumonia. J Rheumatol 1992 ; 19 : 1191-4.
 
18. Mekinian A, Durand-Joly I, Hatron PY, et al. Pneumocystis jirovecii, abstr. PO14. 10th Int. Workshops Opportunistic Protists, Boston, MA, 28 to 31 May 2008.
 
19. Martin-Garrido I, De La Horra C, Respaldiza N, et al. Cigarette smoking is a major risk factor for Pneumocystis jirovecii colonization in chronic obstructive pulmonary disease, abstr. PO40. 10th Int. Workshops Opportunistic Protists, Boston, MA, 28 to 31 May 2008.
 
20. Vananuvat P, Suwannalai P, Sungkanuparph S, et al. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. Semin Arthritis Rheum 2011 ; 41 : 497-502.
PubMed
21. Petri M, Allbritton J. Antibiotic allergy in systemic lupus erythematosus : a case-control study. J Rheumatol 1992 ; 19 : 265-9.
 
22. Demoruelle MK, Kahr A, Verilhac K, et al. Recent-onset systemic lupus erythematosus complicated by acute respiratory failure. Arthritis Care Res (Hoboken) 2013 ; 65 : 314-23.
PubMed
23. Minowa K, Nakiri Y, Lee S, et al. Examination of availability of the criteria for protective therapy against Pneumocystis pneumonia. Nihon Rinsho Meneki Gakkai Kaishi 2009 ; 32 : 256-62.
PubMed
24. 免疫疾患に合併するニューモシスチス肺炎の予防基準. 厚生労働省免疫疾患の合併症と治療法に関する研究班. 2004年度報告書.
 
25. Mori S, Sugimoto M. Pneumocystis jirovecii infection : an emerging threat to patients with rheumatoid arthritis. Rheumatology (Oxford) 2012 ; 51 : 2120-30.
PubMed
26. Falagas ME, Manta KG, Betsi GI, et al. Infectio n-related morbidity and mortality in patients with connective tissue diseases : a systematic review. Clin Rheumatol 2007 ; 26 : 663-70.
 
27. Thomas CF, Limper AH. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol 2007 ; 5 : 298-308.
PubMed
28. Limper AH, Offord KP, Smith TF, et al. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989 ; 140 : 1204-9.
PubMed
29. Benfield TL, Vestbo J, Junge J, et al. Prognostic value of interleukin-8 in AIDS-associated Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1995 ; 151 : 1058-62.
PubMed
30. Aoki Y, Iwamoto M, Kamata Y, et al. Prognostic ind icators related to death in patients with Pneumocystis pneumonia associated with collagen vascular diseases. Rheumatol Int 2009 ; 29 : 1327-30.
 
P.146 掲載の参考文献
1. Thomas CF Jr, Limper AH. Pneumocystis pneumonia : clinical presentation and diagnosis in patients with and without acquired immune deficiency syndrome. Semin Respir Infect 1998 ; 13 : 289-95.
PubMed
2. de Boer MG, Bruijnesteijn van Coppenraet LE, Gaasbeek A, et al. An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients : interhuman transmission or a common environmental source? Clin Infect Dis 2007 ; 44 : 1143-9.
PubMed
3. Yazaki H, Goto N, Uchida K, et al. Outbreak of Pneumocystis jiroveci pneumonia in renal transplant recipients : P. jiroveci is contagious to the susceptible host. Transplantation 2009 ; 88 : 380-5.
 
4. Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008 ; 67 : 189-94.
PubMed
5. Mori S, Sugimoto M. Pneumocystis jirovecii infection : an emerging threat to patients with rheumatoid arthritis. Rheumatology 2012 ; 51 : 2120-30.
PubMed
6. Koike T, Hariga i M, Inokuma S, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 2009 ; 36 : 898-906.
 
7. Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan : interim analys is of 3881 patients. Ann Rheum Dis 2011 ; 70 : 2148-51.
 
8. Koike T, Harigai M, Ishiguro N, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients : postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol 2012 ; 22 : 498-508.
PubMed
9. Sato T, Inokuma S, Maezawa R, et al. Clinical characteristics of Pneumocystis carinii pneumonia in patients with connective tissue diseas es. Mod Rheumatol 2005 ; 15 : 191-7.
 
10. Iikuni N, Kitahama M, Ohta S, et al. Evaluation of Pneumocystis pneumonia inf ection risk factors in patients with connective tissue disease. Mod Rheumatol 2006 ; 16 : 282-8.
 
11. Tokuda H, Sakai F, Yamada H, et al. Clinical and radiolo gical features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndro me : a multicenter study. Intern Med 2008 ; 47 : 915-23.
 
12. Enomoto T, Azuma A, Matsumoto A, et al. Preventive effect of sulfamethoxasole-trimethoprim on Pneumocystis jiroveci pneumonia in patients with interstitial pneumonia. Intern Med 2008 ; 47 : 15-20.
PubMed
13. Limper AH, Offord KP, Smith TF, et al. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989 ; 140 : 1204-9.
PubMed
14. Wright TW, Gigliotti F, Finkelstein JN, et al. Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia. J Clin Invest 1999 ; 104 : 1307-17.
 
15. Koetz K, Bryl E, Spickschen K, et al. T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci U S A 2000 ; 97 : 9203-8.
PubMed
16. Wagner UG, Koetz K, W eyand CM, et al. Perturbation of the T cell repertoire in rheumatoid arthritis. Proc Natl Acad Sci U S A 1998 ; 95 : 14447-52.
 
17. Mori S, Cho I, Ichiyasu H, et al. Asymptomatic carriage of Pneumocystis jiroveci in elderly patients with rheumatoid arthritis in Japan : a possible association between colonization and development of Pneumocystis jiroveci pneumonia during low-dose MTX therapy. Mod Rheu matol 2008 ; 18 : 240-6.
 
18. Kameda H, Tokuda H, Sakai F, et al. Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents : importance of Pneumocystis pneumonia in Japan revealed by a multicenter study. Intern Med 2011 ; 50 : 305-13.
PubMed
19. Tasaka S, Hasegawa N, Kobayashi S, et al. Serum indicators for the diagno sis of pneumocystis pneumonia. Chest 2007 ; 131 : 1173-80.
 
20. Mori S, Cho I, Sugimoto M. A followup study of asymptomatic carriers of Pneumocystis jiroveci during immunosuppressive therapy for rheumatoid arthritis. J Rheumatol 2009 ; 36 : 1600-5.
 
21. Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004 ; 350 : 2487-98.
PubMed
22. Harigai M, Koike R, Miyasaka N. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med 2007 ; 357 : 1874 -6.
 
23. Morris A, Sciurba FC, Lebedeva IP, et al. Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. Am J Respir Crit Care Med 2004 ; 170 : 408-13.
PubMed
24. Calderon EJ, Regordan C, Medrano FJ, et al. Pneumocystis carinii infection in patients with chronic bronchial disease. Lancet 1996 ; 347 : 977.
PubMed
25. Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1977 ; 297 : 1419-26.
PubMed
26. Beard CB, Carter JL, Keely SP, et al. Genetic variation in Pneumocystis carinii isolates from different geographic regions : implications for transmission. Emerg Infect Dis 2000 ; 6 : 265-72.
PubMed
27. Sepkowitz KA. Pneumocysti s carinii pneumonia without acquired immunodeficiency syndrome : who should receive prophylaxis? Mayo Clin Proc 1996 ; 71 : 102-3.
 
28. Komano Y, Harigai M, Koike R, et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab : a retrospective review and case-control study of 21 patients. Arthritis Rheum 2009 ; 61 : 305-12.
PubMed
29. Dumoulin A, Mazars E, Seguy N, et al. Transmission of Pneumocystis carinii disease from immunocompetent cont acts of infected hosts to susceptible hosts. Eur J Clin Microbiol Infect Dis 2000 ; 19 : 671-8.
 
30. Tasci S, Ewig S, Burghard A, Luderitz B. Pneumocystis carinii pneumonia. Lancet 2003 ; 362 : 124.
PubMed
31. Rabodonirina M, Vanhems P, Couray-Targe S, et al. Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalized with HIV-infected patients. Emerg Infect Dis 2004 ; 10 : 1766-73.
PubMed
32. Mori S, Cho I, Sugimoto M. A cluster of Pneumocystis jirovecii infection among outpatients with rheumatoid arthritis. J Rheumatol 2010 ; 37 : 1547-8.
 
P.162 掲載の参考文献
1. Fauci AS, Macher AM, Longo DL, et al. NIH conference. Acquired immunodeficiency syndrome : epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med 1984 ; 100 : 92-106.
PubMed
2. Sepkowitz KA. Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis 1993 ; 17 : S416-22.
PubMed
3. Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia : a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984 ; 100 : 663-71.
PubMed
4. Mansharamani NG, Garland R, Delaney D, et al. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995 : comparison of HIV-associated cases to other immunocompromised states. Chest 2000 ; 118 : 704-11.
PubMed
5. Sepkowitz KA. Pneumocystis carinii pneumonia among patients with neoplastic disease. Semin Respir Infect 1992 ; 7 : 114-21.
PubMed
6. Goorin AM, Hershey BJ, Levin MJ, et al. Use of trimethoprim-sulfamethoxazole to prevent bacterial infections in children with acute lymphoblastic leukemia. Pediatr Infect Dis 1985 ; 4 : 265-9.
PubMed
7. Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1977 ; 297 : 1419-26.
PubMed
8. Hughes WT, Rivera GK, Schell MJ, et al. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1987 ; 316 : 1627-32.
PubMed
9. van Eys J, Berry DM, Crist W, et al. Effect of trimethoprim/sulfamethoxazole prophylaxis on outcome of childhood lymphocytic leukemia. A Pediatric Oncology Group Study. Cancer 1987 ; 59 : 19-23.
 
10. Mahindra AK, Grossman SA. Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors. J Neurooncol 2003 ; 63 : 263-70.
PubMed
11. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002 ; 20 : 1375-82.
PubMed
12. Okita Y, Narita Y, Miyakita Y, et al. Reactivation of cytomegalovirus following treatment of malignant glioma with temozolomide. Int Canc Conf J 2012 ; 1 : 53-7.
 
13. Fossieck BE Jr, Spagnolo SV. Pneumocystis carinii pneumonitis in patients with lung cancer. Chest 1980 ; 78 : 721-2.
PubMed
14. Neuville M, Borie R, Rodier JM, et al. Pneumocystis pneumonia in a patient treated with pemetrexed for non small cell lung cancer. Rev Mal Respir 2010 ; 28 : 97-100.
 
15. Velcheti V, Govindan R. Pneumocystis pneumonia in a patient with non-small cell lung cancer (NSCLC) treated with pemetrexed containing regimen. Lung Cancer 2007 ; 57 : 240-2.
 
16. de la Horra C, Varela JM, Fernandez-Alonso J, et al. Association between human-Pneumocystis infection and small-cell lung carcinoma. Eur J Clin Invest 2004 ; 34 : 229-35.
PubMed
17. Mori H, Ohno Y, Ito F, et al. Polymerase chain reaction positivity of Pneumocystis jirovecii during primary lung cancer treatment. Jpn J Clin Oncol 2010 ; 40 : 658-62.
PubMed
18. Tolaney SM, Partridge AH, Sheib RG, et al. Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer. J Clin Oncol 2006 ; 24 : 5330-1.
PubMed
19. Tolaney SM, Najita J, Winer EP, et al. Lymphopenia associated with adjuvant anthracycline/taxane regimens. Clin Breast Cancer 2008 ; 8 : 352-6.
PubMed
20. De Castro N, Xu F, Porcher R, et al. Pneumocystis jirovecii pneumonia in renal transplant recipients occurring after discontinuation of prophylaxis : a case-control study. Clin Microbiol Infect 2010 ; 16 : 1375-7.
PubMed
21. Green H, Paul M, Vidal L, et al. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients : systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007 ; 82 : 1052-9.
PubMed
22. Neumann S, Krause SW, Maschmeyer G, et al. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2013 ; 92 : 433-42.
PubMed
23. Armstrong W, Meshnick S, Kazanjian P. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in immunocompromised patients. Microbes Infect 2000 ; 2 : 61-7.
PubMed
24. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 1998 ; 113 : 1215-24.
PubMed
P.169 掲載の参考文献
1. Torres HA, Chemaly RF, Storey R, et al. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients. Eur J Clin Microbiol Infect Dis 2006 ; 25 : 382-8.
PubMed
2. De Castro N, Neuvill S, Sarfati C, et al. Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation : a 6-year retrospective study. Bone Marrow Transplant 2005 ; 36 : 879-83.
 
3. Sepkowitz KA, Brown AE, Telzak EE, et al. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 1992 ; 267 : 832-7.
 
4. El Ghoul R, Eckardt SM, Mukhopadhyay S, et al. Fever and dyspnea in a 61-year-old woman with metastatic breast cancer. Chest 2009 ; 136 : 634-8.
 
5. Henson JW, Jalaj JK, Walker RW, et al. Pneumocystis carinii pneumonia in patients with primary brain tumors. Arch Neurol 1991 ; 48 : 40 6-9.
 
6. Sepkowitz KA, Brown AE, Armstrong D. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. More patients, same risk. Arch Intern Med 1995 ; 155 : 1125-8.
PubMed
7. Catherinot E, Lanternier F, Bougnoux ME, et al. Pneumocystis jirovecii Pneumonia. Infect Dis Clin North Am 2010 ; 24 : 107-38.
PubMed
8. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients : a global perspective. Biol Blood Marrow Transplant 2009 ; 15 : 1143-238.
PubMed
9. Tasaka S, Tokuda H. Pneumocystis jirovecii pneumonia in non-HIV-inf ected patients in the era of novel immunosuppressive therapies. J Infect Chemother 2012 ; 18 : 793-806.
 
10. Dixon WG, Abrahamowicz M, Beauchamp ME, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis : a nested case-control analysis. Ann Rheum Dis 2012 ; 71 : 1128-33.
 
11. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989 ; 11 : 954-63.
PubMed
12. Pitchenik AE, Ganjei P, Torres A, et al. Sputum examination for the diagnosis of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Am Rev Respir Dis 1986 ; 133 : 226-9.
 
13. Bigby TD, Margolskee D, Curtis JL, et al. The usefulness of induced sputum in the diagnosis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. Am Rev Respir Dis 1986 ; 133 : 515-8.
 
14. Kovacs JA, Ng VL, Masur H, et al. Diagnosis of Pneumocystis carinii pneumonia : improved detection in sputum with use of monoclonal antibodies. N Engl J Med 1988 ; 318 : 589-93.
PubMed
15. Silva RM, Bazzo ML, Borges AA. Induced sputum versus bronchoalveolar lavage in the diagnosis of pneumocystis jiroveci pneumonia in human immunodeficiency virus-positive patients. Braz J Infect Dis 2007 ; 11 : 549-53.
 
16. Limper AH, Offord KP, Smith TF, et al. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989 ; 140 : 1204-9.
PubMed
17. Jacobs JA, Dieliman MM, Cornelissen EI, et al. Bronchoalveolar lavage fluid cytology in patients with Pneumocystis carinii pneumonia. Acta Cytol 2001 ; 45 : 317-26.
PubMed
18. Azoulay E, Bergeron A, Chevret S, et al. Polymerase chain reaction for diagnosing pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates. Chest 2009 ; 135 : 655-61.
PubMed
19. Mandell GL, Bennett JE, Dolin R, et al. Mandell, Douglas, and Bennett's principles and practice of infectious diseases, 7th Ed. Chapter 270. Pneumocystis Species, Treatment. London : Churchill Livingstone, 2009.
 
P.177 掲載の参考文献
1. Maini R, Henderson KL, Sheridan EA, et al. Increasing Pneumocystis pneumonia, England, UK, 2000-2010. Emerg Infect Dis 2013 ; 19 : 386-92.
 
2. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome : associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996 ; 71 : 5-13.
PubMed
3. Sepkowitz KA, Brown AE, Telzak EE, et al. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 1992 ; 267 : 832.
 
4. Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004 ; 17 : 770.
PubMed
5. Sepkowitz KA, Brown AE, Armstrong D. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. More patients, same risk. Arch Intern Med 1995 ; 155 : 1125.
PubMed
6. Fishman JA. Prevention of infection due to Pneumocystis carinii. Antimicrob Agents Chemother 1998 ; 42 : 995-1004.
PubMed
7. Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004 ; 17 : 770-82.
PubMed
8. Gordon SM, LaRosa SP, Kalmadi S, et al. Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin Infect Dis 1999 ; 28 : 240-6.
PubMed
9. de Boer MG, Bruijnesteijn van Coppenraet LE, Gaasbeek A, et al. An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients : Interhuman transmission or a common environmental source? Clin Infect Dis 2007 ; 44 : 1143-9.
PubMed
10. Oz HS, Hughes WT. Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. J Infect Dis 1997 ; 175 : 901-4.
PubMed
11. Neff RT, Jindal RM, Yoo DY, et al. Analysis of USRDS : incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation 2009 ; 88 : 135-41.
PubMed
12. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007 ; 357 : 2601-14.
PubMed
13. Lufft V, Kliem V, Behrend M, et al. Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. Transplantation 1996 ; 62 : 421-3.
PubMed
14. Goto N, Oka S. Pneumocystis jirovecii pneumonia in kidney transplantation. Transpl Infect Dis 2011 ; 13 : 551-8.
PubMed
15. Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis 2001 ; 33 : 1397-405.
PubMed
16. Arend SM, Westendorp RF, Kroon FP, et al. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin Infect Dis 1996 ; 22 : 920-5.
 
17. Le Gal S, Damiani C, Rouille A, et al. A cluster of Pneumocystis infections among renal transplant recipients : molecular evidence of colonized patients as potential infectious sources of Pneumocystis jirovecii. Clin Infect Dis 2012 ; 54 : e62-71
 
18. Pifer LL, Hughes WT, Stagno S, et al. Pneumocystis carinii infection : evidence for high prevalence in normal and immunosuppressed children. Pediatrics 1978 ; 61 : 35-41.
PubMed
19. Wakefield AE, Lindley AR, Ambrose HE, et al. Limited asymptomatic carriage of Pneumocystis jiroveci in human immunodeficiency virus-infected patients. J Infect Dis 2003 ; 187 : 901-8.
PubMed
20. Rabodonirina M, Vanhems P, Couray-Targe S, et al. Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalized with HIV-infected patients. Emerg Infect Dis 2004 ; 10 : 1766-73.
PubMed
21. Morris A, Beard CB, Huang L. Update on the epidemiology and transmission of Pneumocystis carinii. Microbes Infect 2002 ; 4 : 95-103.
PubMed
22. Bartlett MS, Lee CH, Lu JJ, et al. Pneumocystis carinii detected in air. J Eukaryot Microbiol 1994 ; 41 : 75S.
PubMed
23. Olsson M, Sukura A, Lindberg LA, et al. Detection of Pneumocystis carinii DNA in filtration of air. Scand J Infect Dis 1996 ; 28 : 279-82.
PubMed
24. Wakefield AE. DNA sequences identical to Pneumocystis carinii f. sp. carinii and Pneumocystis carinii f. sp. hominis in samples of air spora. J Clin Microbiol 1996 ; 34 : 1754-9.
PubMed
25. Lundgren B, Elvin K, Rothman LP, et al. Transmission of Pneumocystis carinii from patients to hospital staff. Thorax 1997 ; 52 : 422-4.
PubMed
26. Morris A, Wei K, Afshar K, et al. Epidemiology and clinical significance of Pneumocystis colonization. J Infect Dis 2008 ; 197 : 10-7.
PubMed
27. Miller RF, Ambrose HE, Wakefield AE. Pneumocystis carinii f. sp. hominis DNA in immunocompetent health care workers in contact with patients with P. carinii pneumonia. J Clin Microbiol 2001 ; 39 : 3877-82.
 
28. Vargas SL, Ponce CA, Gigliotti F, et al. Transmission of Pneumocystis carinii DNA from a patient with P. carinii pneumonia to immunocompetent contact health care workers. J Clin Microbiol 2000 ; 38 : 1536-8.
 
29. Hughes WT. Natural mode of acquisition for de novo infection with Pneumocystis carinii. J Infect Dis 1982 ; 145 : 842-8.
 
30. Manoloff ES, Francioli P, Taffe' P, et al. Risk for Pneumocystis carinii transmission among patients with pneumonia : a molecular epidemiology study. Emerg Infect Dis 2003 ; 9 : 132-4.
PubMed
31. Yazaki H, Goto N, Uchida K, et al. Outbreak of Pneumocystis jiroveci pneumonia in renal transplant recipients : P. jiroveci is contagious to the susceptible host. Transplantation 2009 ; 88 : 380-5.
 
32. Tasaka S, Hasegawa N, Kobayashi S, et al. Serum indicators for the diagnosis of Pneumocystis pneumonia. Chest 2007 ; 131 : 1173-80.
 
33. DeLorenzo LJ, Huang CT, Maguire GP, et al. Roentgenographic patterns of Pneumocystis carinii pneumonia in 104 patients with AIDS. Chest 1987 ; 91 : 323-7.
PubMed
34. Limper AH, Offord KP, Smith TF, et al. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989 ; 140 : 1204-9.
PubMed
35. Azoulay E, Bergeron A, Chevret S, et al. Polymerase chain reaction for diagnosing Pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates. Chest 2009 ; 135 : 655-61.
PubMed
36. Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004 ; 350 : 2487-98.
PubMed
37. Ribes JA, Limper AH, Espy MJ, et al. PCR detection of Pneumocystis carinii in bronchoalveolar lavage specimens : analysis of sensitivity and specificity. J Clin Microbiol 1997 ; 35 : 830-5.
PubMed
38. Karageorgopoulos DE, Qu JM, Korbila IP, et al. Accuracy of b-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia : a meta-analysis. Clin Microbiol Infect 2013 ; 19 : 39-49.
 
39. Watanabe T, Yasuoka A, Tanuma J, et al. Serum (1→3) beta-Dglucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis 2009 ; 49 : 1128-31.
 
40. Matsumura Y, Shindo Y, Iinuma Y, et al. Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes. BMC Infect Dis 2011 ; 11 : 76.
PubMed
41. Kaplan JE, Benson C, Holmes KH, et al ; Centers for Disease Control and Prevention (CDC) ; National Institutes of Health ; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents : recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009 ; 58 (RR-4) : 1-207.
 
42. Naderer O, Nafziger AN, Bertino JS Jr. Effects of moderate-dose versus high-dose trimethoprim on serum creatinine and creatinine clearance and adverse reactions. Antimicrob Agents Chemother 1997 ; 41 : 2466-70.
PubMed
43. Martin SI, Fishman JA ; AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant 2009 ; 9 : S227-33.
PubMed
44. Briel M, Bucher HC, Boscacci R, et al. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection. Cochrane Database Syst Rev 2006 ; 3 : CD006150.
PubMed
45. Magne D, Angoulvant A, Botterel F, et al. Pneumocystosis : a network survey in the Paris area 2003-2008. Eur J Clin Microbiol Infect Dis 2011 ; 30 : 673-5.
PubMed
46. Mansharamani NG, Garland R, Delaney D, et al. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995 : comparison of HIV-associated cases to other immunocompromised states. Chest 2000 ; 118 : 704-11.
PubMed
47. Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 2002 ; 34 : 1098-107.
PubMed
48. Godeau B, Coutant-Perronne V, Le Thi Huong D, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease : report of 34 cases. J Rheumatol 1994 ; 21 : 246-51.
 
49. Schmoldt S, Schuhegger R, Wendler T, et al. Molecular evidence of nosocomial Pneumocystis jirovecii transmission among 16 patients after kidney transplantation. J Clin Microbiol 2008 ; 46 : 966-71.
PubMed
50. Arichi N, Kishikawa H, Mitsui Y, et al. Cluster outbreak of Pneumocystis pneumonia among kidney transplant patients within a single center. Transplant Proc 2009 ; 41 : 170-2.
PubMed
51. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus : U. S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). MMWR Recomm Rep 1999 ; 48 (RR-10) : 1-66.
 
52. Mussini C, Pezzotti P, Antinori A, et al. ; Changes in Opportunistic Prophylaxis (CIOP) Study Group. Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients : a randomized trial by the CIOP Study Group. Clin Infect Dis 2003 ; 36 : 645-51.
 
53. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV : Longterm management of the transplant recipient. IV. 7.1 Late infections. Pneumocystis carinii pneumonia. Nephrol Dial Transplant 2002 ; 17 (Suppl 4) : 36-9.
 
54. Kasiske BL, Zeier MG, Chapman JR, et al. ; Kidney Disease : Improving Outcomes. KDIGO clinical practice guideline for the care of kidney transplant recipients : a summary. Kidney Int 2010 ; 77 : 299-311.
PubMed
55. Batiuk TD, Bodziak KA, Goldman M. Infectious disease prophylaxis in renal transplant patients : a survey of US transplant centers. Clin Transplant 2002 ; 16 : 1-8.
PubMed
56. Sassi M, Ripamonti C, Mueller NJ, et al. Outbreaks of Pneumocystis pneumonia in 2 renal transplant centers linked to a single strain of Pneumocystis : implications for transmission and virulence. Clin Infect Dis 2012 ; 54 : 1437-44.
PubMed
57. Gianella S, Haeberli L, Joos B, et al. Molecular evidence of interhuman transmission in an outbreak of Pneumocystis jirovecii pneumonia among renal transplant recipients. Transpl Infect Dis 2010 ; 12 : 1-10.
 
58. Siegel JD, Rhinehart E, Jackson M, et al ; Health Care Infection Control Practices Advisory Committee. 2007 Guideline for isolation precautions : preventing transmission of infectious agents in healthcare settings, June 2007. Am J Infect Control 2007 ; 25 : S65-164.
 
P.186 掲載の参考文献
1. Fein AM, Feinsilver SH, Niederman MS, et al. When the pneumonia doesn't get better. Clin Chest Med 1987 ; 8 : 529-41.
 
2. Mundy LM, Auwaerter PG, Oldach D, et al. Community-acquired pneumonia : impact of immune status. Am J Respir Crit Care Med 1995 ; 152 : 1309-15.
PubMed
3. Hoyo I, Linares L, Cervera C, et al. Epidemiology of pneumonia in kidney transplantation. Transplant Proc 2010 ; 42 : 2938-40.
PubMed
4. Dooley KE, Golub J, Goes FS, et al. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002 ; 34 : 1607-12.
PubMed
5. Mansharamani NG, Garland R, Delaney D. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995 : comparison of HIV-associated cases to other immunocompromised states. Chest 2000 ; 118 : 704-11.
PubMed
6. Tasaka S, Tokuda H, Sakai F, et al. Comparison of clinical and radiological features of pneumocystis pneumonia between malignancy cases and acquired immunodeficiency syndrome cases : a multicenter study. Intern Med 2010 ; 49 : 273-81.
 
7. Charles FT, Andrew HL. Pneumocystis Pneumonia. N Engl J Med 2004 ; 350 : 2487-98.
 
8. Ainoda Y, Hirai Y, Fujita T, et al. Analysis of clinical features of non-HIV Pneumocystis jirovecii pneumonia. J Infect Chemother 2012 ; 18 : 722-8.
PubMed
9. Catherinot E, Lanternier F, Bougnoux ME. Pneumocystis jirovecii Pneumonia. Infect Dis Clin North Am 2010 ; 24 : 107-38.
PubMed
10. Kovacs JA, Masur H. Evolving health effects of Pneumocystis : one hundred years of progress in diagnosis and treatment. JAMA 2009 ; 301 : 2578-85.
PubMed
11. Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome. The National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia. N Engl J Med 1990 ; 323 : 1500-4.
 
12. Briel M, Bucher H, Boscacci R, et al. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection. The Cochrane Library DOI : 10.1002/14651858. CD006150.
 
13. Moon SM, Kim T, Sung H, et al. Outcomes of moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients. Antimicrob Agents Chemother 2011 ; 55 : 4613-8.
PubMed
14. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 1998 ; 113 : 1215-24.
PubMed
15. Martin SI, Fishman JA. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant 2009 ; 9 : S227-233.
PubMed
16. Kahn MR, Fallahi A, Kim MC. Coronary artery disease in a large renal transplant population : implications for management. Am J Transplant 2011 ; 11 : 2665-74.
 
17. Green H, Paul M, Vidal L, et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2007 ; 3 : CD005590.
PubMed
18. Gabardi S, Millen P, Hurwitz S, et al. Atovaquone versus trimethoprim-sulfamethoxazole as Pneumocystis jirovecii pneumonia prophylaxis following renal transplantation. Clin Transplant 2012 ; 26 : E184-90.
PubMed
19. Paul M, Zemer-Wassercug N, Talker O, et al. Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia? Clin Microbiol Infect 2011 ; 17 : 1581-6.
PubMed

書評

最近チェックした商品履歴

Loading...